Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Oncology Letters
      • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Biomedical Reports
      • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • Information for Authors
    • Information for Reviewers
    • Information for Librarians
    • Information for Advertisers
    • Conferences
  • Language Editing
Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • For Authors
    • For Reviewers
    • For Librarians
    • For Advertisers
    • Conferences
  • Language Editing
Login Register Submit
  • This site uses cookies
  • You can change your cookie settings at any time by following the instructions in our Cookie Policy. To find out more, you may read our Privacy Policy.

    I agree
Search articles by DOI, keyword, author or affiliation
Search
Advanced Search
presentation
International Journal of Functional Nutrition
Join Editorial Board Propose a Special Issue
Print ISSN: 2634-7989 Online ISSN: 2634-7237
Journal Cover
January-December 2026 Volume 7 Issue 1

Full Size Image

Sign up for eToc alerts
Recommend to Library

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

Medicine International

An International Open Access Journal Devoted to General Medicine.

Journal Cover
January-December 2026 Volume 7 Issue 1

Full Size Image

Sign up for eToc alerts
Recommend to Library

  • Article
  • Citations
    • Cite This Article
    • Download Citation
    • Create Citation Alert
    • Remove Citation Alert
    • Cited By
  • Similar Articles
    • Related Articles (in Spandidos Publications)
    • Similar Articles (Google Scholar)
    • Similar Articles (PubMed)
  • Download PDF
  • Download XML
  • View XML
Review Open Access

A simple perspective of carbohydrates in food and nutrition (Review)

  • Authors:
    • Sheersha Pradhan
    • Vasudev Anbalagan
    • Jadi Venkatesh
    • Thangamuthu Mohan Das
  • View Affiliations / Copyright

    Affiliations: Department of Chemistry, Venkatraman Ramakrishnan Block, School of Basic and Applied Sciences, Central University of Tamil Nadu, Thiruvarur, Tamil Nadu 610005, India
    Copyright: © Pradhan et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY 4.0].
  • Article Number: 4
    |
    Published online on: June 8, 2026
       https://doi.org/10.3892/ijfn.2026.56
  • Expand metrics +
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Cited By (CrossRef): 0 citations Loading Articles...

This article is mentioned in:


Abstract

Carbohydrates are considered as one of the three primary macronutrients in the realm of food and nutrition in the daily human diet. In addition to being a source of food, they encompass a vast category of natural products, along with synthetic bio‑mimics, which have found suitable applications in therapeutics and drug design. The present review discusses the importance of carbohydrates for a healthy diet, their sources from plants and animals, and their classification. Information on the biological and chemical changes in carbohydrates in the human body, as well as their therapeutic and drug‑design applications, is also provided. The present review provides a narrative review and perspective, integrating nutritional, biochemical and therapeutic perspectives on carbohydrates. The objective was to provide an updated, interdisciplinary overview that connects dietary carbohydrate intake with metabolic processes and emerging medicinal applications.

1. Introduction

Food is essential for survival and maintaining the overall well-being of all living organisms, and the method of food consumption has evolved throughout history. In order to survive, the diet of an individual requires a balance of both nutritious and antinutritional factors. The diet provides nutrients that serve as raw materials for metabolic processes (1,2), and health is greatly influenced by genetics, diet, lifestyle and nutrition. The gastrointestinal system of the human body processes carbohydrates, dietary fats and proteins that are consumed into monosaccharides, fatty acids and amino acids, respectively, fueling organ function and supporting cellular growth (3,4).

In the 21st century, factors such as climate change, water scarcity, rising food prices and population growth challenge agriculture and food security, particularly in arid and semi-arid regions. Scientists and nutritionists need to explore alternative food sources to address hunger and poverty. Cereal grains are the global primary food source and are central to the human diet (5).

Carbohydrates are a major macronutrient, vital for energy production and organ function. The majority of carbohydrates are biodegradable and biocompatible, thus rendering them suitable for both drug delivery and functional foods. Nanostructured carbohydrates, with self-assembling abilities, provide diverse applications in food and therapeutics. Different saccharide structures enable various self-assembly methods, thereby expanding their functions in food (6). Carbohydrates are unique among macronutrients in not having a minimum dietary requirement.

Increase in global health risks, such as type 2 diabetes, obesity, non-alcoholic fatty liver disease (NAFLD) and other cardiovascular health issues, have compelled the scientific community to re-evaluate carbohydrate intake (7). Large-scale epidemiological studies and controlled human trials are increasingly demonstrating that, rather than quantity alone, carbohydrate quality may be the cause of health risks (8). Rapidly digestible starches and heavily processed foods containing refined sugar increase the risk of developing hyperinsulinemia, hepatic de novo lipogenesis (DNL) and postprandial glycemic excursions, whereas fiber-rich sugars reduce the risks of developing these disorders and support metabolic flexibility (9-11). This has opened views on carbohydrate toxicity, which depicts excessive intake of certain digestible carbohydrates, particularly fructose-rich sugars, as a metabolic stressor capable of disrupting hepatic and systemic homeostasis (12,13). Non-digestible carbohydrates, such as resistant starches and oligosaccharides selectively nourish beneficial gut microbes, leading to the production of bioactive metabolites, such as short-chain fatty acids, that help regulate glucose and support immune function (14,15).

Carbohydrates also contribute greatly to medicine development. Both natural and synthetic sugar-based polymers and glycoconjugates exhibit excellent biocompatibility, molecular and biological recognition, and structural tunability, facilitating a wide range of applications in biological evaluations, such as anticancer and antiviral therapies (16). Technical utilities, such as automated glycan assembly, have further improved the access to complex sugar structure (17), speeding up translational research connecting chemistry, biology and medicine.

The present narrative review presents a comprehensive perspective on carbohydrates, focusing on their physicochemical characteristics, nutritional values and chemical and metabolic functions. Furthermore, contemporary topics, such as carbotoxicity and fructose-induced lipogenesis are also discussed. Unlike the highly specialized reviews, the present review aimed to connect carbohydrate chemistry with food science and nutritional values, providing an interdisciplinary overview relevant to students, researchers, health professionals and nutritionists.

2. Physicochemical properties of carbohydrates and their biological significance in food matrices

The structural hierarchy and complex structural features of carbohydrates influence their nutritional values to a great extent. Monosaccharides, such as glucose and fructose, are the simplest monomeric forms of sugar. Through the formation of glycosidic bonds, these units assemble into disaccharides (for example, sucrose) and eventually into polysaccharides with vast, complex chains that define the texture and energy profile of the human diet. A few common examples of carbohydrates are illustrated in Fig. 1 (18,19). Furthermore, polysaccharides are utilized in various functions, including energy storage in plants (primarily starch) and as structural support for plant cells (primarily cellulose). They function as a gelling component of the intercellular matrix to help hold ions, such as sodium, calcium and magnesium. Polysaccharides, such as cellulose, starch, chitin and seaweed polysaccharides have high commercial value across various industries, from paper manufacturing to food processing (20).

Molecular structure of representative
monosaccharides (panels 1-3), disaccharides (panels 4-6) and
polysaccharides (panel 7).

Figure 1

Molecular structure of representative monosaccharides (panels 1-3), disaccharides (panels 4-6) and polysaccharides (panel 7).

The physicochemical properties of carbohydrates are fundamental factors that affect their functions in food matrices and biological evaluation. These properties, ranging from solubility and hygroscopicity to gelation capacity and reactivity, arise directly from molecular structure, including monomer composition, glycosidic linkage stereochemistry (α vs. β), branching density and molecular weight (21). Such structural features influence not only the texture, stability and sensory properties of foods, but also the rate and extent of their digestion, thus affecting glycemic response and interactions with the gut microbiota (22).

Solubility and hygroscopicity are vital properties influencing food quality and shelf life. Monosaccharides, such as glucose and fructose exhibit high water solubility due to their multiple hydroxyl groups, thereby reducing the reactivity of water with food and inhibiting microbial growth (23), which is utilized in confectionery and baked goods to maintain softness and moisture. However, polysaccharides, such as cellulose are insoluble due to β(1→4) linkages that result in extensive intermolecular hydrogen bonding, which contributes to dietary fiber content and textural bulk without significantly affecting water activity (24). The solubility of carbohydrates also affects phase behavior in complex matrices; for instance, during the preparation of gummy sweets, incompatibility between gelatin and long-chain polysaccharides in glucose syrups can lead to phase separation, which is modulated by moisture content and the presence of small-molecule additives, such as citric acid or allulose (25).

Carbohydrate physicochemistry is also controlled by viscosity and gelation. Starch, composed of amylose [linear glucan connected through α(1→4)-linkage] and amylopectin [branched with α(1→6) linkages], undergoes gelation upon heating in aqueous media, leading to swelling of the system, loss of crystallinity and formation of a viscoelastic network (26). The ratio of amylose to amylopectin critically influences the gel strength and retrogradation kinetics; a higher amylose content improves gelation but also increases the risk of staling in bakery products (27). Similarly, pectin, a heteropolysaccharide rich in galacturonic acid, forms gels in acidic, high-sugar environments through charge neutralization and water loss, a mechanism essential for jam and jelly preparation. Recent research has demonstrated that processing technologies, including ultrasound-assisted heat-moisture treatment, can modify starch crystallinity and reduce rapidly digestible starch content, thereby lowering glycemic potential while preserving functional properties (28).

Carbohydrate reactivity, particularly through the Maillard reaction, markedly affects both food quality and nutritional outcomes. This non-enzymatic browning reaction occurs between reducing sugars (e.g., glucose, fructose) and the amino groups of proteins at elevated temperatures and in the presence of moisture, generating flavor compounds, brown pigments and advanced glycation end-products (29). While it improves the flavor in roasted coffee or seared meat, etc., uncontrolled Maillard reactions in processed foods can produce potentially harmful compounds and decrease protein bioavailability (30). On the contrary, controlled Maillard reactions between proteins and prebiotic fibers can enhance emulsifying properties, solubility and antioxidant activity, thereby enhancing the functionality of plant-based products (31). Non-reducing sugars such as sucrose do not participate in the Maillard reaction if not hydrolyzed first to glucose and fructose, emphasizing how glycosidic bond affects reactivity.

The biological significance of these physicochemical traits becomes evident in their modulation of carbohydrate bioavailability and gut health. Rapidly digestible starches, often resulting from extensive gelatinization and low amylose content, elicit sharp postprandial glucose spikes, which can contribute to metabolic disorders when consumed chronically (24). By contrast, resistant starches and non-digestible oligosaccharides, characterized by β-linkages or complex branching that are inaccessible to human amylases, reach the colon intact, where they serve as prebiotics, selectively stimulating beneficial bacteria such as Lactobacilli and Bifidobacteria (32,33). The fermentation of these fibers produces short-chain fatty acids (SCFAs), such as butyrate, which nourish colonocytes, regulate immune function and improve insulin sensitivity (34). The efficacy of prebiotic action is highly dependent on physicochemical parameters: Molecular weight, solubility and glycosidic bond type determine fermentability rates and microbial selectivity (35).

Moreover, the food matrix itself modulates carbohydrate bioaccessibility. Encapsulation within cell walls (as in whole grains) or complexation with proteins and lipids can attenuate enzymatic hydrolysis, reducing glycemic impact (36). Processing methods, both thermal (e.g., baking and extrusion) and non-thermal (e.g., high-pressure processing), can disrupt these matrices, increasing starch digestibility, or they can promote retrogradation and resistant starch formation, depending on conditions (37). Thus, the interplay between intrinsic carbohydrate properties and extrinsic matrix factors ultimately shapes nutritional outcomes.

The physicochemical properties of carbohydrates are not only technical aspects for food formulation but are crucial to their biological outcomes. These properties influence texture and stability in food products, regulate glycemic response and modulate the gut microbiota, thereby connecting food science and human physiology (9,11). The strategic manipulation of carbohydrate structure through breeding, enzymatic modification, or customized processing provides promising opportunities to create foods that meet sensory expectations while enhancing metabolic health (38).

3. Nutritional aspects of carbohydrates in the human diet

Dietary sources and bioavailability

The bioavailability of carbohydrates, the rate and extent to which they are absorbed and utilized, is intrinsically linked to their structural hierarchy and the food matrix in which they reside (9). Dietary carbohydrates range from simple monosaccharides to complex polysaccharides. Monosaccharides, such as glucose and fructose are present in their free form in honey, fruits and corn syrups, providing immediate bioavailability. Disaccharides, such as the lactose found in mammalian milk or the sucrose concentrated in sugar beets and cane, require minimal enzymatic cleavage prior to absorption (39). While animal-derived foods are generally carbohydrate-poor, dairy products are a unique exception, providing the essential disaccharide lactose, which accounts for almost 40% of the energy in human breast milk and is vital for neonatal development (40,41).

Contemporary nutritional science emphasizes that the health impact of these sugars is heavily dictated by their source. For instance, while refined sucrose and fructose in high-fructose corn syrup are associated with rapid glycemic spikes, the same sugars found within the fibrous matrix of whole fruits such as grapes or kiwi exhibit different kinetic profiles (42,43). As the structural complexity of polysaccharides, such as the starches found in legumes, tubers and cereal grains, increases, the pace of digestion typically slows. However, modern processing techniques have challenged the traditional dichotomy between simple and complex. Current evidence indicates that highly processed complex carbohydrates, such as white bread or instant rice, can have a glycemic index (GI) equal to or higher than that of simple table sugar, leading to significant insulin demand and increasing the risk of metabolic syndromes, obesity and ovulatory infertility (44). The role of carbohydrates in the diet is presented in Table I (41,44-61). Table I provides an overview of dietary carbohydrates, which are vital macronutrients; their types, quantity and metabolic fate critically influence health outcomes.

Table I

Source of various carbohydrates and diseases related to excess intake.

Table I

Source of various carbohydrates and diseases related to excess intake.

Category of carbohydratesType of carbohydrateSweetness (relative to sucrose=1)Food sourceDaily amountAmount of energy (caloric value kcal/g)Activity on the body partsCarbohydrate toxicity or diseases(Refs.)
MonosaccharidesGlucose0.75Dates, currants, figs, grapes, dried apricot, sweet corn, and honey25 g4BloodHyperglycemia, diabetes(44-48)
 fructose1.74Honey, dates, fruit jams, grapes, apples, pear, kiwi and banana≤50 g4Livernon-alcoholic fatty liver disease (NAFLD)(45,47,49-51)
 Galactose0.32Flavored yogurts, lactose free milk, ground black peppers5-20 g4ovariesOvarian cancer(44,47,52)
DisaccharidesSucrose1Cakes, cookies, and dark chocolate, beetroot, carrots, sugar cane and sugar beet20-32 g4Heart, breastheart disease, breast cancer(47,53-55)
 lactose0.2Milk, buttermilk, yogurt, sour cream, condensed milk, Frozen, cottage cheese, evaporated milk, goats milk and ice creams12 g4intestineLactose intolerance(47,54,56,41)
 maltose0.4Malted wheat and barley, Breads, bagels, Malt extract, molasses Beer75 mg4Digestive systemChronic diarrhea(47,54,55,4)
OligosaccharideFructooligosacch aride0.3-0.6Legumes, cabbage, broccoli, Onion, fennel, peas, wheat, bananas, asparagus, garlic10-2 0 g4NANot specific toxicity(47,57,58)
 Galactooligosacch arides0.3-0.6Cow milk, yogurt, beans.12-15 g4NANA(47,59)
PolysaccharidesStarchNot sweetOats, rice, chickpeas, potato, pasta, corn, flours.NA4NANA(47)
 FiberNot sweetCereal grains, legumes, nuts, seeds.28-36 g2NANA(60,61)

[i] NA, not available.

The interaction between dietary carbohydrates, the gut microbiome, and host health constitutes a dynamic and reciprocal relationship that is fundamental to modern nutritional frameworks. Dietary fibers and other indigestible carbohydrates serve as pivotal environmental factors influencing the composition and metabolic output of the gut microbial ecosystem (62). Subsequently, the gut microbiota converts these dietary elements into bioactive metabolites that affect host metabolism, immune function and even neurological processes (63). This relationship is increasingly recognized in the prevention and management of chronic diseases, including obesity, cardiometabolic disorders and certain types of cancer (62). The notion of carbohydrate quality currently includes not only its glycemic effects, but also its capacity to support a beneficial gut microbiota, thereby enhancing overall health (9,11). This integrated viewpoint emphasizes that the simplistic perception of carbohydrates as mere caloric sources is outdated; they should be regarded as information-rich molecules whose chemical language is deciphered by both human enzymes and the trillions of microbial entities in the gut, ultimately defining their significant biological roles in food and nutrition sciences (34,64).

Role as a primary energy substrate

Carbohydrates are the main source of oxidative fuel for the human body, providing with ~4 kcal/g (17 kJ/g) of energy. Glucose is particularly critical as it is the only metabolic substrate for the central nervous system and red blood cells, which lack the enzymes to efficiently oxidize other fuels under normal physiological conditions (65,66). In the fed state, dietary carbohydrates maintain blood glucose homeostasis and replenish glycogen stores in the liver and skeletal muscle. Under restricted exogenous intake, the body demonstrates metabolic flexibility by activating gluconeogenesis and ketogenesis to maintain brain function. This change indicates that the quality of carbohydrates is critical for overall health. A balanced intake (usually 45-65% of daily calories) maintains a stable metabolism; however, consuming high-GI foods continuously break down these homeostatic mechanisms (67-70).

Non-digestible polysaccharides, or dietary fiber, have become an integral part of modern preventive medicine. Unlike starch, which is broken down by enzymes in the small intestine, fibers such as cellulose and hemicellulose remain whole until they reach the colon. There, they add bulk to the stool and serve as fermentable substrates for the gut microbiota (71). The SCFAs produced by this process serve as an alternative energy source for colonocytes and exert systemic anti-inflammatory effects (72). Current clinical guidelines suggest that individuals should consume ~30 g of fiber per day, which is linked to lower rates of coronary heart disease, type 2 diabetes and colorectal cancer (73). This indicates that carbohydrate chemistry can affect long-term health outcomes.

Despite the extensive understanding of carbohydrate metabolism, a significant knowledge gap persists regarding inter-individual variability in glycemic response. While tools such as the GI and glycemic load provide a standardized framework for ranking foods, contemporary big data nutrition studies (74) have revealed that two individuals consuming the identical carbohydrate source can exhibit vastly different postprandial glucose excursions. This variability is deemed to be driven by a complex interplay between host genetics, sleep patterns, physical activity, and most crucially the unique composition of the gut microbiome of an individual (74,75).

Furthermore, a vigorous scientific debate remains unresolved concerning the carbohydrate-insulin model (CIM) of obesity. Proponents of the CIM argue that high-carbohydrate diets drive obesity by promoting insulin secretion, which partitions energy toward fat storage rather than oxidation, whereas critics maintain that total energy balance (calories in vs. calories out) remains the primary driver (76,77). Resolving these questions is essential for moving beyond one-size-fits-all dietary guidelines and toward personalized nutritional interventions that can effectively combat the global rise in metabolic disease.

Authoritative international dietary guidelines and the disadvantages of the overconsumption of refined carbohydrates

Authoritative international dietary guidelines consistently identify refined carbohydrates as a key dietary component to limit due to their well-established association with chronic disease risk. The World Health Organization (WHO), in its global recommendations, explicitly advises that the intake of free sugars, which encompass added sugars and those naturally present in honey, syrups and fruit juices, should be limited to <10% of total energy intake for both adults and children, with a further conditional recommendation to reduce this to <5% for additional health benefits (78,79). This guidance is grounded in extensive epidemiological evidence linking a high sugar consumption to weight gain, dental caries and metabolic dysfunction. Similarly, the Dietary Guidelines for Americans (DGA), jointly issued by the US Department of Health and Human Services and the US Department of Agriculture, emphasize minimizing the intake of refined grains and added sugars, recommending that <10% of daily calories should be derived from added sugars and that at least half of all grain consumption should be whole grains (80). The European Food Safety Authority (EFSA) and national bodies such as the UK Scientific Advisory Committee on Nutrition (SACN) echo these principles, advocating for a shift from refined to whole-grain carbohydrate sources to improve long-term health outcomes (81).

The scientific foundation for these guidelines rests on a robust body of epidemiological research. The landmark Prospective Urban Rural Epidemiology (PURE) study, which followed >135,000 individuals across 18 countries, provided critical population-level evidence that high carbohydrate intake, particularly from refined sources, is associated with an increased total mortality (82). This finding challenged older paradigms that focused primarily on fat reduction and highlighted the importance of carbohydrate quality over mere quantity. Further analysis from the PURE cohort specifically linked the higher consumption of refined grains (median intake of 350 g/day in the highest quintile) to a significantly elevated risk of developing major cardiovascular events and total mortality. By contrast, whole grain intake exhibited neutral or protective associations (83). These results underscore the differential health impacts of carbohydrate subtypes, a nuance increasingly emphasized in modern nutritional science.

Longitudinal cohort studies from the USA have provided granular insights into specific refined carbohydrate sources. Data from the Nurses' Health Study and the Health Professionals Follow-Up Study (84) demonstrate a clear dose-response association between the consumption of sugar-sweetened beverages (SSBs) and the incidence of type 2 diabetes and cardiovascular disease. A meta-analysis of prospective cohort studies confirmed that each daily serving of SSBs is associated with an 18% higher risk of coronary heart disease (85). Similarly, a previous systematic review and meta-analysis found that the higher intake of refined carbohydrates predicts a significantly increased risk of developing type 2 diabetes, with the association persisting even after adjustment for body mass index and other confounders (86). The mechanisms underlying these associations are multifactorial: Refined carbohydrates drive rapid postprandial glycemia and hyperinsulinemia, promote hepatic DNL leading to dyslipidemia (elevated triglycerides and reduced high-density lipoprotein cholesterol) and induce systemic inflammation, all key pathways in the development of cardiometabolic diseases (87).

The concept of ultra-processed foods (UPFs), as defined by the NOVA classification system, has further refined the understanding of the risks associated with the consumption of refined carbohydrates. UPFs are industrial formulations that typically contain high levels of refined starches, added sugars and unhealthy fats, while being low in fiber and phytonutrients. A recent umbrella review of epidemiological meta-analyses concluded that a higher consumption of UPFs is consistently associated with increased risks of obesity, type 2 diabetes, cardiovascular disease and all-cause mortality (88). The Framingham Offspring Study reported that for every 10% increase in the proportion of UPFs in the diet, there was a 12% higher risk of overall cardiovascular disease and a 13% higher risk of cerebrovascular disease (89). These findings suggest that the health risks of consuming refined carbohydrates may be amplified in the context of ultra-processing, where the food matrix is degraded and hyper-palatable combinations override natural satiety signals, leading to excess energy intake and metabolic stress (87).

Despite this strong consensus, some nuances and ongoing debates exist. For instance, not all refined carbohydrate sources carry equal risk; the consumption of white rice in Asian populations exhibits complex associations that may be modified by the overall dietary pattern and glycemic load (83). Furthermore, the focus is shifting from isolated nutrients to holistic dietary patterns. The Mediterranean diet, rich in whole grains, legumes, fruits and vegetables, has been shown in randomized trials, such as the PREDIMED study, to significantly reduce cardiovascular events, demonstrating that the adverse effects of the consumption of refined carbohydrates can be mitigated by replacing them with high-quality carbohydrate sources within a balanced dietary pattern (90). Overall, authoritative guidelines and contemporary epidemiological evidence converge on a clear message that reducing the intake of refined carbohydrates, particularly in the form of added sugars and UPFs, is a critical public health strategy for preventing chronic diseases globally.

4. Metabolic processes and bioenergetics involving carbohydrates

The transition from the structural complexity of dietary carbohydrates to systemic energy requires a highly coordinated sequence of enzymatic transformations. For the human body, the critical connection between food and health is realized through these metabolic pathways, which determine whether a carbohydrate is partitioned toward immediate adenosine triphosphate (ATP) production, biosynthetic precursors, or long-term energy storage. Cells use different enzymatic activities in different phases to convert ingested glucose into carbon dioxide and water. Two metabolic pathways, glycolysis and the tricarboxylic acid (TCA) cycle, also known as the Krebs or citric acid cycle, are involved in the breakdown of glucose (91).

Glycolysis

Glycolysis is a catalytic process that converts glucose into pyruvate via 10 enzyme steps. These highly regulated processes of glycolysis have two stages: The energy input for Step 1 requires two ATPs per glucose molecule, followed by the energy release as four ATPs, two for each glyceraldehyde molecule, which is described as Step 2(90). Glycolysis, a process in living cells, can also be used in the citric acid cycle or fermentation, and is the primary source of acetyl coenzyme A (acetyl-CoA), the primary energy source. The structures of glycolysis intermediates are depicted in Fig. 2 (92).

Simple schematic representation of
glycolysis pathway. ADP, adenosine diphosphate; ATP, adenosine
triphosphate; NAD, nicotinamide adenine dinucleotide; NADH,
nicotinamide adenine dinucleotide + hydrogen.

Figure 2

Simple schematic representation of glycolysis pathway. ADP, adenosine diphosphate; ATP, adenosine triphosphate; NAD, nicotinamide adenine dinucleotide; NADH, nicotinamide adenine dinucleotide + hydrogen.

The initial stage of glycolysis requires energy in the form of ATP. ATP phosphorylates D-glucose at the six carbons via the enzyme hexokinase to produce D-glucose-6-phosphate (G-6-P). This regulatory process is inhibited by the presence of glucose-6-phosphate. Phosphoglucoisomerase (class: Isomerase) then converts it to D-fructose-6-phosphate (F-6-P), which is phosphorylated again by ATP, this time at the one-carbon position, by the enzyme phosphofructokinase (class: Transferase) to produce D-fructose-1,6-bisphosphate. Owing to its high G value, this is the committed stage of glycolysis. The enzyme, fructose bisphosphate aldolase, then cleaves D-fructose-1,6-bisphosphate into two three-carbon molecules, dihydroxyacetone phosphate (DHAP) and D-glyceraldehyde-3-phosphate (G-3-P). DHAP is transformed into G-3-P as the following step in glycolysis requires the molecule G-3-P by the enzyme triose phosphate isomerase (93).

The second stage involves producing four ATP molecules for each glucose molecule. The glyceraldehyde-3-phosphate dehydrogenase enzyme phosphorylates G-3-P at the one carbon to produce the high-energy molecule, 1,3-bisphosphoglycerate (BPG). Phosphoglycerate kinase then phosphorylates adenosine diphosphate (ADP) at the expense of BPG to produce ATP and 3-phosphoglycerate. Phosphoglycerate mutase then converts 3-phosphoglycerate to 2-phosphoglycerate to produce another high-energy molecule. Enolase then converts 2-phosphoglycerate to phosphoenolpyruvate, releasing water, potassium and manganese ions. Pyruvate kinase phosphorylates ADP to produce ATP and pyruvate, and cellular energy controls this reaction. High energy levels indicate inhibited pyruvate kinase. Stage 2 occurs twice due to glucose division (93).

In parallel, G-6-P can be diverted into the hexose monophosphate shunt (pentose phosphate pathway). Unlike glycolysis, this pathway is not primarily concerned with ATP production. Instead, it serves two vital biosynthetic roles: Generating nicotinamide adenine dinucleotide phosphate, which provides reducing power for fatty acid synthesis and antioxidant defense (reducing glutathione), and producing ribose-5-phosphate, a precursor for nucleotide synthesis (94). In the context of nutrition, the balance between these two pathways is essential; for instance, a diet chronically high in refined sugars can over-activate these shunt pathways, potentially fueling DNL and contributing to metabolic dysfunction (95).

Krebs cycle

The citric acid cycle is the ultimate oxidative process in which carbs, lipids and amino acids interact. It is the most significant metabolic pathway for the energy source of the body. TCA is the most essential core metabolic pathway, connecting nearly all metabolic processes. The Krebs cycle (Fig. 3) is an aerobic biodegradation process that begins with acetyl-CoA and ends with CO2. Patients with diabetes have lower oxaloacetic acid and Krebs cycle activity due to reduced glucose and pyruvate levels (96).

Schematic representation of the Krebs
cycle. NAD, nicotinamide adenine dinucleotide; NADH, nicotinamide
adenine dinucleotide + hydrogen; CoASH, coenzyme A; GTP, guanosine
triphosphate.

Figure 3

Schematic representation of the Krebs cycle. NAD, nicotinamide adenine dinucleotide; NADH, nicotinamide adenine dinucleotide + hydrogen; CoASH, coenzyme A; GTP, guanosine triphosphate.

At higher energy levels, the citrate synthesis rate increases, while the flux through the Krebs cycle decreases. This excess citrate is subsequently transported to the cytosol and degraded to acetyl-CoA. Acetyl-CoA can then be used to produce fatty acids and cholesterol. Citrate has a positive regulatory effect on lipogenic enzymes (e.g., acetyl-CoA carboxylase) and a negative regulatory effect on phosphofructokinase-1 (a glycolytic enzyme). Citrate is also necessary for ketogenesis in non-hepatic tissues (96).

The α-ketoglutarate dehydrogenase complex converts α-KG to succinyl coenzyme A (succinyl-CoA) through multiple steps (Fig. 3). Succinyl-CoA is a highly energetic molecule that generates the only guanosine triphosphate molecule in this pathway when succinate thiokinase is present (96). Nicotinamide adenine dinucleotide (NADH2) and flavin adenine dinucleotide (FADH2) are the energy molecules created during this oxidative decarboxylation cycle. These molecules release energy during the oxidative phosphorylation reaction; thus, their power is retained in ATP as high-energy phosphate (97). Contemporary biochemical evidence suggests that the total aerobic yield from a single glucose molecule is ~30-32 ATP. This efficiency highlights why carbohydrates remain the preferred primary energy substrate of the human body. However, this high-efficiency system is also sensitive to nutrient overload. When carbohydrate intake exceeds the capacity for oxidation and glycogen storage, the excess acetyl-CoA is redirected toward triglyceride synthesis, reinforcing the link between high-glycemic diets and adipose tissue expansion (98).

Energy balance and glycemic response

One glucose molecule is transformed into 38 ATP molecules during cellular respiration. One glucose molecule is broken up to produce two molecules of pyruvate, producing eight ATP directly from anaerobic glycolysis. Each three-carbon pyruvate yields one NADH2 (equivalent to three ATP) during the pyruvate decarboxylation reaction. As a result, each six-carbon glucose molecule in this process generates six ATP. The total energy produced by each three-carbon pyruvate in the Krebs cycle is 12 ATP (91).

This quantity is generated by isocitrate dehydrogenase (+NADH2 3ATP), alpha-ketoglutarate dehydrogenase (+NADH2=3ATP), malate dehydrogenase (+NADH2=3 ATP), succinate dehydrogenase (+FADH2=2 ATP) and succinate thiokinase (+GTP). As each six-carbon glucose molecule generates two three-carbon pyruvate molecules, the total quantity produced by one glucose molecule is 24 ATP. The glycolysis 8 ATP, the pyruvate dehydrogenase complex 6 ATP, and the Krebs cycle 24 ATP combine to yield 38 ATP (91).

The systemic health impact of carbohydrate metabolism is best observed through the glycemic response, the postprandial rise and fall of blood glucose. This response is governed by a delicate hormonal ‘tug-of-war’ between insulin and glucagon (99). High-bioavailability carbohydrates (simple sugars and refined starches) elicit a rapid insulin spike, which promotes glucose uptake via GLUT4 transporters in muscle and adipose tissue, while simultaneously suppressing lipolysis (99,100).

The connection here involves metabolic flexibility. In a healthy individual, the body can switch seamlessly between carbohydrate oxidation in the fed state and fat oxidation in the fasted state. However, a diet dominated by high-GI foods can lead to chronic hyperinsulinemia and eventual insulin resistance. This state represents a breakdown in systemic energy balance: Cells become starved of glucose despite elevated blood glucose levels, leading to increased hunger and a cycle of metabolic stress (44). Understanding these pathways emphasizes that the nutritional value of a carbohydrate is defined not only by its caloric content, but by its kinetic interaction with the body's metabolic machinery.

Divergent hepatic kinetics: Fructose vs. glucose metabolism

While glucose and fructose are structural isomers sharing the same caloric density, their metabolic destinies in the human body are fundamentally different due to divergent hepatic processing (101). Glucose metabolism is systemic; although the liver is a primary site for its regulation, glucose is utilized by nearly every cell in the body, and its entry into glycolysis is strictly governed by the energy status of the cell. By contrast, fructose is almost exclusively metabolized by the liver, and its entry into central metabolic pathways bypasses the most critical regulatory checkpoints (101,102).

The primary kinetic distinction lies in the first steps of phosphorylation. Glucose is converted to G-6-P by hexokinase or glucokinase. Fructose, however, is phosphorylated by fructokinase (ketohexokinase or KHK) to form fructose-1-phosphate (F-1-P). This enzyme is not inhibited by ATP or citrate. Furthermore, F-1-P is cleaved by aldolase B into DHAP and glyceraldehyde. These triose phosphates enter the glycolytic sequence downstream of the phosphofructokinase-1 (PFK-1) regulatory step (103,104). Essentially, the excess of fructose in the metabolic machinery provides a continuous supply of carbon precursors, such as acetyl-CoA, regardless of the actual energy requirements of the cell (105). Additionally, the subsequent conversion of fructose-6-phosphate to fructose-1,6-bisphosphate by PFK-1 is the rate-limiting step of glycolysis. When cellular ATP levels are high, PFK-1 is inhibited, decelerating glucose oxidation to prevent an unnecessary surplus of metabolic intermediates (103).

This unregulated flux has profound implications for metabolic health. As the liver is suddenly presented with an abundance of acetyl-CoA that it cannot oxidize in the TCA cycle, it must divert these carbons toward DNL. This leads to the synthesis of palmitate and other fatty acids, contributing to the accumulation of intrahepatic fat (non-alcoholic fatty liver disease, NAFLD) and the secretion of very-low-density lipoprotein, which raises blood triglyceride levels (106).

Furthermore, the rapid, uncontrolled phosphorylation of fructose by KHK leads to transient intracellular ATP depletion. As ATP is rapidly consumed to phosphorylate fructose without the brake of feedback inhibition, the resulting rise in AMP triggers the purine degradation pathway, leading to the production of uric acid. Elevated uric acid is not only a risk factor for gout, but also functions as a pro-oxidant within the hepatocyte, potentially inducing mitochondrial oxidative stress and further impairing insulin sensitivity (107,108). This kinetic reality explains why high-fructose diets, particularly those rich in refined syrups, are uniquely linked to metabolic syndrome, independent of total caloric intake.

Role of resistant starches and oligosaccharides in shaping the gut microbiota and the risk of metabolic disease

Resistant starches and oligosaccharides represent two critical classes of non-digestible carbohydrates that exert profound influence on gut microbial ecology and, consequently, on the risk of developing metabolic diseases, such as obesity, type 2 diabetes and cardiovascular disorders. Their biological significance stems not from caloric contribution, since they largely escape digestion in the small intestine, but from their role as selective substrates for beneficial gut commensals, thereby modulating microbial composition, metabolic output and host physiology (15).

Resistant starch is a form of starch that resists enzymatic hydrolysis by human amylases and reaches the colon intact, where it serves as a fermentable substrate for specific members of the gut microbiota. Primary degraders of resistant starch include Ruminococcus bromii and Bifidobacterium adolescentis, with emerging evidence identifying additional specialists such as Ruminococcoides bili (109). These bacteria initiate the breakdown of complex resistant starch granules through specialized carbohydrate-active enzymes (CAZymes), enabling secondary fermenters to access the resulting oligosaccharides and monosaccharides. This hierarchical degradation process fosters cross-feeding networks, thereby enhancing microbial diversity and stability. The fermentation of resistant starch predominantly yields SCFAs, notably butyrate, acetate and propionate, which serve as key mediators of metabolic health. Butyrate, in particular, is the preferred energy source for colonocytes, strengthens the gut barrier by upregulating tight junction proteins, and exerts anti-inflammatory effects by inhibiting histone deacetylases and activating G-protein-coupled receptors (e.g., GPR109A). Clinical and preclinical studies consistently link higher a intake of resistant starch with improved insulin sensitivity, reduced adiposity and lower systemic inflammation, all of which are protective against cardiometabolic diseases (24,62).

Oligosaccharides, such as fructooligosaccharides (FOS), galactooligosaccharides and human milk oligosaccharides, function similarly as prebiotics by selectively stimulating the growth and activity of beneficial bacteria, especially Bifidobacteria and certain Lactobacilli. Their structural complexity, defined by glycosidic linkage types [e.g., β(2→1) in inulin-type FOS] and the degree of polymerization, determines their resistance to host enzymes and specificity for microbial utilization. Research profiling the metabolic capacities of 17 gut commensal strains has revealed marked strain-specific differences in oligosaccharide fermentation, underscoring that prebiotic efficacy is contingent on both substrate structure and the recipient's microbial repertoire (110). This individualized response explains the variable outcomes observed in dietary interventions and highlights the need for personalized nutrition approaches. The SCFAs produced from oligosaccharide fermentation regulate host metabolism through multiple pathways: propionate reduces hepatic lipogenesis and gluconeogenesis, while acetate influences appetite regulation via central nervous system signaling (62). Moreover, oligosaccharides can directly inhibit pathogen adhesion by acting as decoy receptors, thereby enhancing gut defense mechanisms.

The interplay between these carbohydrates and the gut microbiome has significant implications for the prevention of chronic disease. Dietary fibers, including RS and oligosaccharides, are associated with a reduced risk of obesity, type 2 diabetes and types of certain cancer, largely through microbiota-dependent mechanisms (62,111). For instance, low-carbohydrate diets that inadvertently reduce fiber intake may diminish SCFA production, potentially compromising gut barrier integrity and promoting endotoxemia, a known driver of insulin resistance (111). Conversely, the strategic inclusion of high-quality, fermentable carbohydrates supports a resilient microbial ecosystem that buffers against dysbiosis induced by Western diets high in refined sugars and saturated fats (112). Notably, the concept of ‘carbohydrate quality’ now supersedes mere quantity; slowly digestible or non-digestible forms such as resistant starch and oligosaccharides are favored for their ability to modulate postprandial glycemia and sustain microbial health without contributing to hyperinsulinemia or DNL (24,112). Hence, resistant starches and oligosaccharides function as keystone dietary components that shape a health-promoting gut microbiota, drive beneficial metabolic signaling via SCFAs, and mitigate risk factors for major chronic diseases, positioning them at the nexus of food science, microbiome research and precision nutrition.

Despite these advances however, challenges remain in translating findings into universal dietary recommendations due to inter-individual variability in gut microbiota composition, host genetics and baseline metabolic status. Furthermore, the structural heterogeneity of dietary carbohydrates complicates analytical characterization and standardization. Emerging glycomic platforms combining chromatography and mass spectrometry are beginning to address these gaps by enabling precise mapping of carbohydrate structures to microbial responses (34).

5. The global intake trends of dietary fiber

In the 1970s, Burkitt's research (113,114) led to a resurgence of scientific interest in dietary fiber (97). Subsequent research has demonstrated a connection between the consumption of dietary fiber, body weight, metabolic processes and overall health. The consumption of dietary fiber is associated with a favorable body weight, a healthy gut microbiota and a lower risk of cardiovascular disease and mortality. It also enhances intestinal health and lowers the riss of developing cancer. The primary health benefits of dietary fiber and the risks of deficiency are discussed in this synopsis, with particular attention to the effects of abdominal obesity and overall metabolic health (61).

Global dietary fiber intake trends reveal a persistent and concerning gap between recommended levels and actual consumption across most populations worldwide. Current evidence indicates that median intake values typically range from 15 to 20 g per day, substantially below the widely accepted recommendations of 25-38 g per day for adults (8,115). This deficit is particularly pronounced in high- and middle-income countries where dietary patterns have markedly shifted toward energy-dense, nutrient-poor options. Recent global macrotrend analyses demonstrated that while some middle-income countries have experienced modest increases in fiber consumption over the past three decades, these improvements are often offset by concurrent rises in sodium intake and the consumption of UPFs (116). The Swiss National Nutrition Survey provides a compelling case study, demonstrating that a higher consumption of UPFs is significantly associated with a lower dietary fiber intake, highlighting the inverse association between industrial food processing and fiber adequacy (117). Similarly, data from the USA spanning 1999=2017 reveal only minimal increases in fiber consumption, with persistent racial disparities; African Americans consistently exhibit a lower fiber intake compared to other demographic groups, potentially contributing to elevated colorectal cancer rates in this population (118). In Chile, national surveys indicate that fiber intake remains suboptimal despite public health initiatives, with primary sources being traditional staples rather than diverse plant-based foods (119,120).

For example, according to a previous analysis, adults in the USA and Europe ingest 18-24 g of dietary fiber daily for men and 16-20 g for women, with grain products as the main source. This is approximately one-third of what is advised; the majority of Western populations wish to increase their intake by ~50%. According to the NHANES (National Health and Nutrition Examination Survey), dietary fiber intake was higher in European nations than in North American nations (97).

An emerging scientific debate centers on the differential physiological effects of various fiber types and sources, challenging the traditional view of fiber as a homogeneous nutrient category. Contemporary research increasingly distinguishes between isolated and intrinsic fiber, fermentable and non-fermentable varieties, and the impact of fiber across different dietary contexts, including low-carbohydrate and ultra-processed food frameworks. The controversy extends to regulatory definitions, particularly regarding low-molecular-weight carbohydrates, such as oligosaccharides and inulin, which are accepted as dietary fiber in many jurisdictions, but remain optional in the Codex Alimentarius definition, creating inconsistencies in nutritional labeling and research interpretation (121). This debate is further complicated by the recognition that the health benefits of fiber are not merely mechanical, but are profoundly mediated through interactions with the gut microbiome. Different fiber types serve as selective substrates for specific microbial taxa, leading to varied production profiles of SCFAs, such as acetate, propionate and butyrate, which function as critical signaling molecules influencing immune regulation, metabolic homeostasis and even neurocognitive function (62,122,123).

Contemporary evidence from large-scale prospective cohort studies and comprehensive meta-analyses robustly supports the protective role of higher total fiber intake against major chronic diseases. The landmark Lancet systematic review established that every 8-g increase in daily fiber consumption is associated with a 5-27% reduction in mortality and the incidence of coronary heart disease, stroke, type 2 diabetes and colorectal cancer (8). This finding has been reinforced by more recent umbrella reviews encompassing millions of individuals, which confirm strong, credible associations between adequate fiber intake and reduced risk across diverse health outcomes (115). The mechanisms underlying these benefits extend beyond the traditional understanding of the role of fiber in gastrointestinal health to include modulation of the gut-brain axis, the enhancement of gut barrier integrity and the epigenetic regulation of immune function through SCFA-mediated histone deacetylase inhibition (123-125). Furthermore, fiber consumption has demonstrated specific protective effects in vulnerable populations, including the reduced risk of surgery for inflammatory bowel disease (126), improved metabolic parameters in obesity (127,128) and improved glycemic control in diabetes (129,130).

Despite this substantial body of evidence, several critical scientific questions remain unresolved. First, the causal vs. the associative nature of fiber-microbiome-host interactions requires further elucidation through well-designed intervention trials that account for interindividual variability in baseline microbiota composition and host genetics, such as the FUT2 secretor status, which influences microbial niche availability (62,122). Second, optimal dose-response associations for specific fiber types and distinct health endpoints have not been definitively established, rendering precise dietary recommendations challenging (115). Third, the relative efficacy of whole food vs. supplements or fortified foods in promoting long-term adherence and sustained health benefits remains unclear, particularly given the complex food matrix effects that may enhance fiber bioactivity (131,132). Fourth, the impact of modern food processing methods on fiber structure and functionality requires systematic investigation, as industrial processing may alter the physicochemical properties of fiber and, consequently, its biological effects (133,134). Finally, the development of personalized nutrition approaches necessitates a better understanding of how individual factors, including age, sex, metabolic status and existing disease conditions, influence responses to different fiber interventions, which could revolutionize dietary guidance from population-based to precision-based recommendations (135).

6. Medicinal aspects of carbohydrates

Among the bioactive glycosides that have been naturally extracted or derived, O- and N-glycosides are abundant, while C-glycosides (both naturally occurring and laboratory synthesized) make more stable bio-mimics than native O-glycosides as they are not prone to catalytic or enzymatic cleavage (136). These widespread classes of biomolecules play vital roles in immune system function and the stimulation of the immune response, which have yet to be properly explored by researchers. Several such carbohydrate-based drugs developed with potential biological activities are illustrated in Fig. 4 (137,138). Additionally, they have inherent chiral complexity, high bioavailability and excellent biocompatibility, rendering this class of compounds an excellent option for the development of prodrugs (139). Depending on the evidence, some carbohydrate-based medicines are given in Table II (140-157). It underscores the versatility of carbohydrates in drug design, delivery and therapeutic function, while emphasizing the importance of dosage control to minimize adverse effects.

Molecular structures of
carbohydrate-based medicines: Monosaccharides (panels 8, 9 and 10),
disaccharides (panels 11, 12 and 13), tri-saccharides (panel 14),
oligosaccharides (panels 15 and 16), and polysaccharides (panels 17
and 18).

Figure 4

Molecular structures of carbohydrate-based medicines: Monosaccharides (panels 8, 9 and 10), disaccharides (panels 11, 12 and 13), tri-saccharides (panel 14), oligosaccharides (panels 15 and 16), and polysaccharides (panels 17 and 18).

Table II

Medicines derived from carbohydrate sources and their functions.

Table II

Medicines derived from carbohydrate sources and their functions.

Category of carbohydratesTypes of carbohydrateMedicine derived from the carbohydrate (Fig. 4)aActivity on the body partsFunction of the medicineDiseases caused by overdosage of the medicine (side-effects)(Refs.)
MonosaccharidesGlucoseMetformin (no. 8)LiverTo balance the production of glucose in the liver.Induces gastrointestinal disturbance, lactic acidosis, hepatotoxicity, vitamin B12 deficiency, acute pancreatitis, hypoglycemia(140,141)
 GalactoseACEgal anti-inflammatory drug (aceclofenac with D-galactose) (no. 9)Inflammatory tissuesAceclofenac works by blocking the enzyme called cyclooxygenase (COX) which generates prostaglandins that causes pain, fever and inflammationNA(142)
  3-amino-2,3,6-trideoxy-L-lyxo-hexopyranoseDoxorubicin (no. 10)Cancer cellsIt regulates the growth of cancer cells by intercalating into DNA and inhibits the topoisomerase II and further it blocks DNA and RNA synthesis.Cardiotoxicity, neuropathy, hepatotoxicity, nephrotoxicity, alopecia, typhlitis, myelosuppression, neutropenia, anemia, thrombocytopenia, nausea, and diarrhea(143,144)
DisaccharidesSucroseSucralfate (no. 11)gastrointestina l (GI) tractIt stimulates the healing of duodenal ulcers by reducing pepsin activity in gastric juice in the stomach.Constipation, aluminium toxicity, dry mouth & skin, headaches, nausea, vomiting, flatulence, low phosphate levels (hypophosphatemia)(143,145)
 lactoseLactulose (no. 12)colonIt enhances the growth of beneficial bacteria such as Lactobacilli. It draws the water into colon and reduces constipation. It promotes gut health.Lactulose affects the intestine, plasma metabolomes, and nitrogen metabolism.(146,147)
 maltoseFerric carboxymalt ose (FCM)- Medication (no. 13)Bone marrowIt promotes ferric iron into the bloodstream then utilized for the production of red blood cells in the bone marrow and it will be stored in the liver and spleen.Acute renal failure, headache and aseptic meningitis, blood clots(148,149)
TrisaccharidesA trisaccharide moiety attached to a steroidal aglyconeDigoxin (no. 14)HeartIt inhibits sodium-potassium ATPase which leads to the increase of intracellular concentration of sodium and calcium. This leads to a chain of biochemical reactions that show multiple effects on cardiac muscle and the cardiovascular system.Irregular heart rhythms, visual disturbances, confusion, dizziness, nausea and vomiting(143,150)
OligosaccharidesHeparin-derived pentasaccharideFondaparinu x-Injection (prefilled syringe) (no. 15)BloodIt stimulates the action of antithrombin III against Factor Xa and it prevents blood clotting.Headache and gastrointestinal disorders, including diarrhea, nausea and vomiting.(151,152)
 Multiple β-D-xylopyranose units are chemically sulfated and linked togetherPentosan polysulfateBlood (no. 16)It works on the blood where it functions as a heparin-like anticoagulant & reduces the risk of blood clotting and intensifies the process of fibrinolysis.Headache, Nausea,(143,153)
PolysaccharidesStarchSodium starch glycolate (SSG)- pharmaceutic al excipient (no. 17)Stomach and small intestine.It induces the effectiveness of medicines and by speeding up the process of tablet disintegration and drug release.NA(154)
 Ribosylribitol phosphate-carbohydrate-containing medicationHaemophilus influenzae type b (Hib) Vaccine (no. 18)Immune cells in the bloodstream and lymphoid tissues.It is a preventive vaccine protect the infections of the blood.Redness, swelling or pain at the injection site, Low-grade fever, Fatigue.(155-157)

[i] aThe numbers in parentheses correspond to the compound numbers presented in Fig. 4. NA, not available.

Natural sources

Carbohydrates have not only been a major source of food and nutrition but also have excellent pharmaceutical applications. Carbohydrates derived from natural sources have been studied as therapeutic agents for a number of years. Among all carbohydrate-based drugs developed between 2000 and 2021, the majority have been derived from naturally occurring carbohydrate moieties, of which 37% are nucleosides. Furthermore, 60% of all carbohydrate-based drugs have broad applications in the preparation of antiviral, antibacterial/antiparasitic, anticancer and antidiabetic drugs (156). For instance, saponins, a diverse family of glycosides having brilliant adjuvant activity, such as Quillaja brasiliensis saponins (triterpene glycosides). Its source is the Chilean tree Quillaja saponaria bark. It has been reported to have >20 water-soluble Quillaja saponaria saponins, from which several led to the eliciting of humoral and cell-mediated responses (158). Similarly, in Asian countries, Coriolus versicolor polysaccharides (polysaccharides Krestin and Lentinan) have been used for >40 years as antitumor adjuvants (159). Pectin, a family of polysaccharides, is a fine source of dietary fiber. It has been reported to exhibit inhibitory activity against various cancer cell lines (160-164).

Synthetic carbohydrate-based materials

Structures of naturally occurring carbohydrates are often very complex due to their complex biosynthetic pathway. Hence, isolating structurally defined pure compounds from natural sources becomes cumbersome. To better address demands in glycobiology, synthetic carbohydrate derivatives or glycoconjugates comprise a fascinating alternative. Synthetic or non-natural glycoconjugates can aid in understanding structure-activity associations in biological responses and mimic the functions of native saccharide derivatives (165).

Some of the advantages of these synthetic carbohydrate-based materials stem from their biocompatibility and intrinsic biological functionality, resulting in generally low toxicity and excellent biodegradability, which are crucial for clinical translation (166). Their most significant asset is their ability to engage in specific, high-affinity interactions with carbohydrate-binding proteins (lectins, selectins and siglecs) that are central to numerous disease processes, including cancer, inflammation and infection This allows for the rational design of therapeutics that can modulate immune responses; for instance, synthetic glycopolymers can be engineered to mimic the multivalent presentation of glycans on cell surfaces, amplifying binding avidity through the ‘glycocluster effect’ to either activate or suppress immune cells for applications in tumor immunotherapy (167,168). Furthermore, carbohydrate polymers, such as chitosan, alginate and hyaluronic acid serve as excellent scaffolds for targeted drug delivery, particularly for colon-specific release, as they can be degraded by colonic microflora enzymes, thereby minimizing systemic side-effects (169,170). The structural diversity of the sugar scaffold also provides multiple points for chemical modification, enabling fine-tuning of pharmacokinetic properties such as solubility and half-life (171).

Automated glycan assembly (AGA) has expedited access to synthetic glycans up to 50-mers (172), while other automated platforms based on electrochemical assembly (173), fluorous-assisted solution-phase (174) and HPLC-assisted synthesis (175) have been limited to a few examples not exceeding hexasaccharides (176). From the proof-of-concept using a modified peptide synthesizer in 2001 to the first commercial Glyconeer 2.1 synthesizer (177), AGA has been developed using glycans of mammalian, bacterial and plant origin as a precursor (178,179).

The AGA oligosaccharide synthesis workflow is designed to minimize the number of purification steps and manipulations (Fig. 5). Inside the reaction vessel of the synthesizer, a resin-bound linker serves as an anchor for sequentially attaching monosaccharide building blocks. In this manner, excess reagents can be washed away, and time-consuming intermediate purification steps can be avoided. Following synthesis, the resin-bound oligosaccharide is removed from the synthesizer and cleaved from the solid support. Analytical normal-phase high-performance liquid chromatography (NP-HPLC) and MALDI analysis of the crude product after cleavage are used to assess the success of the synthesis qualitatively. The protected glycan is purified using preparative NP-HPLC. Global deprotection removes all permanent protecting groups and following reverse-phase HPLC (RP-HPLC), the unprotected glycan is obtained (177,178,180,181). This enhanced accessibility has directly fueled progress in glycomimetic design, in which natural carbohydrate leads are modified to overcome inherent limitations such as poor metabolic stability and low bioavailability (182). Common strategies include replacing the endocyclic oxygen with carbon (carbasugars) or sulfur (thiosugars), or substituting the glycosidic oxygen with a methylene group to form C-glycosides, all of which confer resistance to enzymatic hydrolysis by glycosidases (183).

A general schematic representation of
AGA oligosaccharide synthesis workflow.

Figure 5

A general schematic representation of AGA oligosaccharide synthesis workflow.

Cyclodextrin (CD)-based materials have garnered applications in the food and pharmaceutical industries since the 1980s. For example, Sugammadex (Bridion), a modified γ-CD, has been used in anesthesia since 2008 and also functions as an antidote to some curare-like muscle relaxants (184). The electrostatic interaction and complex formation of CD with drugs can significantly alter the pharmacokinetic profile of a drug, and CD inclusion complex-based nanofibers have great applications in drug discovery and delivery, as they tend to increase the bioavailability of the drugs (185-187). For instance, the oral delivery of insulin is difficult owing to its instability in the gastric conditions of patients. However, reports suggest that carboxymethyl-β-CD-grafted chitosan (CMCD-g-CS) leads to the more effective oral delivery of insulin at pH 7.4 due to increased insulin bioavailability after pH-triggered complexation with CMCD-g-CS (188).

Other saccharide derivatives, such as imine sugars, have been suggested to function as potent inhibitors to several glycosidases, such as glycogen phosphorylases, glycoside hydrolases and glycosyltransferases. Their inhibitory potency against these carbohydrate-processing enzymes is suggested to depend on structural and electronic similarity to the oxocarbenium transition state of the natural substrate at a physiological pH (189,190).

Additionally, research on carbohydrate-conjugated noble metal-based nanoparticles, such as Au, Ag and Pt, has seen tremendous growth over the past few decades due to their applications in bioimaging, diagnostic imaging, biosensing, gene/drug delivery (targeted/triggered/controlled), targeted therapeutics. Despite their inertness, they can form a stable covalent linkage via facile synthetic methods with compounds containing functional groups, such as thiols and disulfides (16).

7. Carbotoxicity and its relevance to fructose-induced lipogenesis

Even though lipotoxicity (excess of lipids or a specific lipid class) is a more familiar term in the biomedical field, carbotoxicity is gaining increased recognition. The excessive ingestion of carbohydrates has the potential to degrade human health and ultimately cause the development of metabolic syndrome, diabetes, obesity and their multiple co-morbidities. Hence, the concept of ‘carbotoxicity’ was proposed in 2018, stating that non-cellulose-digestible carbohydrates can be toxic to a certain extent (12). Additionally, the PURE cohort study established a link between excessive carbohydrate consumption and adverse health effects worldwide (82). The study involved human subjects, demonstrating that a high intake of carbohydrates could increase the risk of mortality with a hazard ratio (HR) of 1.28 for highest 77.2% vs. lowest 46.4% quintile carbohydrate energy, which is significantly low with increasing fat intake with a HR of 0.77 (35.3 vs. 10.6% quintile energy) or excess protein consumption with a HR 0.88 (19.7 vs. 10.8% quintile energy) (82,191). Additional research has demonstrated that the excess intake of free sugars (monosaccharides and disaccharides) is associated with the risk of DNL in the liver, leading to the accumulation of a large number of lipids and finally resulting in NAFLD; an increase in the hepatic DNL following a high-carbohydrate meal was found in ob/ob mice, Western-diet-fed mice and healthy individuals, which may increase the risk of hepatic steatosis (192). Another study with human trials demonstrated that carbohydrate-restricted diets, otherwise known as ketogenic diets, can serve as a good technique for weight loss and the management of type 2 diabetes (193), along with various antidiabetic therapies, including antidiabetic drugs that effectively improve hyperglycemia and hyperinsulinemia (194-196).

The investigation of fructose-induced lipogenesis through human clinical trials has been pivotal in establishing the mechanistic link between excessive dietary fructose consumption and metabolic dysfunction, forming a core component of carbotoxicity. Carbotoxicity posits that the chronic overconsumption of specific carbohydrates, particularly fructose, drives metabolic disease through the substrate overload of hepatic metabolic pathways, leading to ATP depletion, uric acid generation, mitochondrial stress and transcriptional upregulation of lipogenic enzymes (108). Unlike glucose, which is metabolized in a regulated manner under insulin control, fructose bypasses the rate-limiting enzyme phosphofructokinase, enabling unregulated entry into glycolysis and acetyl-CoA production, thereby fueling DNL, independent of insulin signaling. This property renders it uniquely hepatotoxic at high doses (108,197).

Several landmarks and recent clinical trials have provided robust evidence for this pathway. The foundational study by Schwarz et al (198) demonstrated that even a moderate increase in fructose intake can significantly affect liver metabolism. In that trial, 40 children with obesity were placed on an isocaloric diet, with fructose restricted to 4% of total calories, for 9 days. This intervention resulted in a marked 56% decrease in DNL, a 22% reduction in liver fat and significant improvements in insulin kinetics, all without any change in body weight. This finding was critical, as it established that the lipogenic effects of fructose are direct and rapid, and that its restriction can reverse key features of NAFLD and insulin resistance, independently of weight loss (198).

Building on this, the 2018 randomized crossover trial by Beysen et al (199) provided detailed dose-response data on acute fructose administration in healthy men. The study revealed that fructose feeding acutely and dose-dependently stimulates hepatic fractional DNL, with considerable inter-individual variability in susceptibility. That study quantified the immediate lipogenic potential of fructose and highlighted that not all individuals respond equally, suggesting a role for genetic or metabolic predisposition (199).

More recently, the narrative review by Geidl-Flueck and Gerber (200) and a post-publication peer review (letter to the editor) by Prinz (201) synthesized findings from multiple controlled feeding trials. Their research directly compared beverages sweetened with glucose, fructose and sucrose in healthy men. These studies demonstrated that fructose and sucrose, but not glucose, significantly increased hepatic DNL. These findings were instrumental in differentiating the metabolic effects of monosaccharides, confirming that fructose, as a component of both sucrose and high-fructose corn syrup, is the primary driver of sugar-induced lipogenesis.

The relevance of these trials to carbotoxicity is profound. They provide human experimental evidence validating the biochemical hypothesis: Excess fructose functions as a chronic metabolic stressor. The process begins with fructose metabolism in the liver, which rapidly depletes ATP and generates uric acid, a known inducer of oxidative stress and inflammation (202). Concurrently, the flood of carbon from fructose metabolism provides abundant substrate for DNL. This is further amplified by the activation of key transcription factors, such as carbohydrate-responsive element-binding protein and sterol regulatory element-binding protein-1c, which upregulate the entire lipogenic gene program (203). The resulting increase in the intrahepatic triglyceride content is a hallmark of NAFLD, which is now recognized as the hepatic manifestation of metabolic syndrome (204).

Furthermore, the gut microbiome has emerged as a crucial intermediary in this process. The pivotal study by Zhao et al (205) demonstrated that dietary fructose is not only metabolized by the liver, but also by the gut microbiota, which convert it to acetate. This microbiota-derived acetate is then used by the liver as an additional substrate for DNL, effectively creating a second pathway through which fructose promotes fat synthesis. This finding, highlighted in a commentary by Postic (206), underscores the systemic nature of the metabolic impact of fructose.

The cumulative evidence from these trials paints a consistent picture: Fructose is a potent, direct stimulator of hepatic DNL in humans. This mechanism is central to the pathophysiology of NAFLD, dyslipidemia and insulin resistance, all key components of metabolic syndrome. The concept of carbotoxicity integrates these findings, framing high fructose intake not merely as a source of empty calories, but as a specific metabolic toxin that disrupts hepatic homeostasis through defined molecular and physiological pathways. This understanding shifts the focus of dietary recommendations from simple caloric restriction to the quality of carbohydrate intake, emphasizing the need to limit added sugars, particularly those rich in fructose, to mitigate the risk of chronic metabolic diseases. The slow yet optimal strategy to address carbotoxicity, a potential cause of obesity, is to incorporate physical activity, dietary changes and lifestyle modifications, which can help manage body weight and contribute to improving metabolic syndrome, cardiovascular disease and premature mortality.

8. Future perspectives

Carbohydrates and their derivatives play a crucial role in several biological processes. Researchers have been involved in the synthesis, characterization and applications of carbohydrate derivatives for the past two decades. In continuation of the ongoing projects in carbohydrate chemistry (207-210), the present review attempted to elucidate the role of carbohydrates in nutrition, which further broadened our research area. Scientists are likely to focus on precision nutrition, tailoring carbohydrate composition in foods to individual needs based on genetic and metabolic factors. Socially, a growing demand for sustainable, plant-based options is driving the food industry to innovate with alternative carbohydrate sources. Health-conscious consumers may drive the development of functional carbohydrates with specific health benefits. Advances in biotechnology may lead to genetically modified crops with improved carbohydrate profiles. Additionally, smart packaging technologies could help preserve the freshness and quality of carbohydrate-containing products.

9. Conclusion

Carbohydrates remain one of the most abundant, versatile and biologically influential macronutrients in the human diet. Far from functioning solely as sources of metabolic energy, carbohydrates operate at the intersection of food structure, digestion kinetics, metabolic regulation, microbial ecology and therapeutic innovation. Developments in glycomimetics, carbohydrate-based polymers and automated glycan assembly highlight their expanding role in therapeutics, immunomodulation and targeted drug delivery. Looking ahead, emerging paradigms, such as precision nutrition, microbiome-informed dietary strategies and structure-guided food processing approaches are poised to redefine carbohydrate functionality in both health and disease. In continuation of the ongoing project in carbohydrate chemistry, the present review attempted to briefly consolidate the roles of carbohydrates in the food industry, their nutritional value and their medicinal aspects, emphasizing their function as a critical macronutrient. Understanding the numerous functions of carbohydrates will aid in humans make better dietary decisions that will support their general well-being with healthier diets, functional foods and innovative therapeutics as aligning carbohydrate intake with physiological needs, while minimizing exposure to refined and ultra-processed forms, remains a central, evidence-based strategy for promoting metabolic health and preventing chronic disease in the modern era. The present review emphasizes the connection between carbohydrate-rich foods and human health, while promoting knowledgeable, sensible eating habits. By adopting a narrative review and perspective-based approach, the present review consolidates the current understanding of carbohydrates across nutrition, metabolism and therapeutics, while highlighting emerging concepts, such as carbotoxicity and precision nutrition.

Acknowledgements

SP would like to thank the Central University of Tamil Nadu (CUTN), Thiruvarur, Tamil Nadu, India for the research fellowship and infrastructure facilities. All the authors would like to thank the Central University of Tamil Nadu (CUTN) and DST-FIST (Department of Science and Technology-Fund for Improvement of S&T Infrastructure), for the infrastructure facility. TMD acknowledges Ms. Maruvada Samyuktha and Ms. Banoth Jahnavi, Department of Chemistry, Venkatraman Ramakrishnan Block, School of Basic and Applied Sciences, Central University of Tamil Nadu, Thiruvarur, Tamil Nadu, India for taking part in the preparation of the manuscript by collecting literature.

Funding

Funding: The present study received financial support from SERC DST (Science and Engineering Research Council, Department of Science and Technology), CSIR (Council of Scientific and Industrial Research) and UGC (University Grants Commission), New Delhi, India.

Availability of data and materials

Not applicable.

Authors' contributions

SP and TMD conceptualized the review topic and designed the manuscript framework. VA and JV conducted the literature search and screening of suitable literature. SP and VA wrote the initial draft of the manuscript and the figures/tables were prepared by VA and JV. TMD critically revised the manuscript for important intellectual content and supervised the project. All authors have read and approved the final manuscript. Data authentication is not applicable.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1 

Carocho M, Morales P and Ferreira ICFR: Natural food additives: Quo vadis? Trends Food Sci Technol. 45:284–295. 2015.

2 

Chen Y, Michalak M and Agellon LB: Importance of nutrients and nutrient metabolism on human health. Yale J Biol Med. 91:95–103. 2018.PubMed/NCBI

3 

Moco S, Martin FPJ and Rezzi S: Metabolomics view on gut microbiome modulation by polyphenol-rich foods. J Proteome Res. 11:4781–4790. 2012.PubMed/NCBI View Article : Google Scholar

4 

Román S, Sánchez-Siles LM and Siegrist M: The importance of food naturalness for consumers: Results of a systematic review. Trends Food Sci Technol. 67:44–57. 2017.

5 

Saleh ASM, Zhang Q, Chen J and Shen Q: Millet grains: Nutritional quality, processing, and potential health benefits. Compr Rev Food Sci Food Saf. 12:281–295. 2013.

6 

Lu X, Chen J, Guo Z, Zheng Y, Rea MC, Su H, Zheng X, Zheng B and Miao S: Using polysaccharides for the enhancement of functionality of foods: A review. Trends Food Sci Technol. 86:311–327. 2019.

7 

Mozaffarian D: Dietary and policy priorities for cardiovascular disease, diabetes, and obesity: A comprehensive review. Circulation. 133:187–225. 2016.PubMed/NCBI View Article : Google Scholar

8 

Reynolds A, Mann J, Cummings J, Winter N, Mete E and Te Morenga L: Carbohydrate quality and human health: A series of systematic reviews and meta-analyses. Lancet. 393:434–445. 2019.PubMed/NCBI View Article : Google Scholar

9 

Razouki AS, Hameed WR, Naeem BA, Falaih HH, Nassar SA and Mashchal MB: Metabolic effects of dietary fiber, carbohydrate, glucose, lipid metabolism on human health and nutritional therapy. Curr Clin Med Educ. 3:11–23. 2025.

10 

Svihus B and Hervik AK: Digestion and metabolic fates of starch, and its relation to major nutrition-related health problems: A review. Starch - Stärke. 68:302–313. 2016.

11 

Gao Q, Li Y and Wang L: Dietary Carbohydrate modulation in metabolic syndrome: Mechanistic insights, gut microbiota interactions, and precision nutrition approaches. Food Rev Int. 1–29. 2026.PubMed/NCBI View Article : Google Scholar

12 

Kroemer G, López-Otín C, Madeo F and de Cabo R: Carbotoxicity-noxious effects of carbohydrates. Cell. 175:605–614. 2018.PubMed/NCBI View Article : Google Scholar

13 

Kushwaha R, Vardhan PS and Kushwaha PP: Chronic kidney disease interplay with comorbidities and carbohydrate metabolism: A review. Life (Basel). 14(13)2023.PubMed/NCBI View Article : Google Scholar

14 

Topping DL and Clifton PM: Short-chain fatty acids and human colonic function: Roles of resistant starch and nonstarch polysaccharides. Physiol Rev. 81:1031–1064. 2001.PubMed/NCBI View Article : Google Scholar

15 

Liu H, Zhang M, Ma Q, Tian B, Nie C, Chen Z and Li J: Health beneficial effects of resistant starch on diabetes and obesity via regulation of gut microbiota: A review. Food Funct. 11:5749–5767. 2020.PubMed/NCBI View Article : Google Scholar

16 

Thodikayil AT, Sharma S and Saha S: Engineering carbohydrate-based particles for biomedical applications: Strategies to construct and modify. ACS Appl Bio Mater. 4:2907–2940. 2021.PubMed/NCBI View Article : Google Scholar

17 

Suri J and Gilmour R: Expediting glycospace exploration: Therapeutic glycans via automated synthesis. Angew Chem Int Ed Engl. 64(e202422766)2025.PubMed/NCBI View Article : Google Scholar

18 

Barrett JS and Gibson PR: Fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAPs) and nonallergic food intolerance: FODMAPs or food chemicals? Ther Adv Gastroenterol. 5:261–268. 2012.PubMed/NCBI View Article : Google Scholar

19 

Gilbert RG, Wu AC, Sullivan MA, Sumarriva GE, Ersch N and Hasjim J: Improving human health through understanding the complex structure of glucose polymers. Anal Bioanal Chem. 405:8969–8980. 2013.PubMed/NCBI View Article : Google Scholar

20 

Qi X and Tester RF: Fructose, galactose and glucose-In health and disease. Clin Nutr ESPEN. 33:18–28. 2019.PubMed/NCBI View Article : Google Scholar

21 

Duceac IA, Stanciu MC, Nechifor M, Tanasă F and Teacă CA: Insights on some polysaccharide gel type materials and their structural peculiarities. Gels. 8(771)2022.PubMed/NCBI View Article : Google Scholar

22 

Tharanathan RN: Food-derived carbohydrates-structural complexity and functional diversity. Crit Rev Biotechnol. 22:65–84. 2002.PubMed/NCBI View Article : Google Scholar

23 

K R, S VK, Saravanan P, Rajeshkannan R, Rajasimman M, Kamyab H and Vasseghian Y: Exploring the diverse applications of Carbohydrate macromolecules in food, pharmaceutical, and environmental technologies. Environ Res. 240(117521)2024.PubMed/NCBI View Article : Google Scholar

24 

Garrido-Romero M, Montilla A and Moreno FJ: Dietary carbohydrates: A trade-off between appealing organoleptic and physicochemical properties and ability to control glucose release and weight management. Curr Opin Food Sci. 49(100976)2023.

25 

Wang R, Hartel RW, Zhai X, Fu W, Sun Y and Wang S: Phase separation and gelation of gelatin-glucose syrup mixtures and gummy confections: Effects of moisture content, sugars, citric acid, and citrates. Food Hydrocoll. 153(110006)2024.

26 

Wang Q and Wood P: Carbohydrates: Physical properties. In: Handbook of Food Science, Technology, and Engineering. Hui YH (Ed). Vol. 1. CRC Press: Taylor & Francis, 2005.

27 

Wang Y, Bai Y, Ji H, Dong J, Li X, Liu J and Jin Z: Insights into rice starch degradation by maltogenic α-amylase: Effect of starch structure on its rheological properties. Food Hydrocoll. 124(107289)2021.

28 

Han L, Wei Q, Cao S, Yu Y, Cao X and Chen W: The assisting effects of ultrasound on the multiscale characteristics of heat-moisture treated starch from Agriophyllum squarrosum seeds. Int J Biol Macromol. 187:471–480. 2021.PubMed/NCBI View Article : Google Scholar

29 

Trần TN: The role of physical chemistry in food and beverage. Int J Sci Res Arch. 13:2959–2968. 2024.

30 

Wang R, Zhai X, Hartel RW, Chang Y, Pang W, Han W, Lv H and Wang S: Effects of saccharide type and extended heating on the Maillard reaction and physicochemical properties of high-solid gelatin gels. Food Chem. 459(140249)2024.PubMed/NCBI View Article : Google Scholar

31 

Urango ACM, Meireles MAA and Silva EK: Maillard conjugates produced from proteins and prebiotic dietary fibers: Technological properties, health benefits and challenges. Trends Food Sci Technol. 147(104438)2024.

32 

Wang W, Fan Z, Yan Q, Pan T, Luo J, Wei Y, Li B, Fang Z and Lu W: Gut microbiota determines the fate of dietary fiber-targeted interventions in host health. Gut Microbes. 16(2416915)2024.PubMed/NCBI View Article : Google Scholar

33 

Lu X, Dai X, He W, Ma S and Gong N: Prebiotic Effects of Polysaccharides and Their Influence on Lactobacilli. In: Exploring Lactobacilli: Biology, Roles and Potential Applications in Food Industry and Human Health. Laranjo M (Ed.), IntechOpen, 2025.

34 

Lee H, Song J, Lee B, Cha J and Lee H: Food carbohydrates in the gut: Structural diversity, microbial utilization, and analytical strategies. Food Sci Biotechnol. 33:2123–2140. 2024.PubMed/NCBI View Article : Google Scholar

35 

Hernandez-Hernandez O, Sabater C, Calvete-Torre I, Doyagüez EG, Muñoz-Labrador AM, Julio-Gonzalez C, de las Rivas B, Muñoz R, Ruiz L, Margolles A, et al: Tailoring the natural rare sugars D-tagatose and L-sorbose to produce novel functional carbohydrates. NPJ Sci Food. 8(74)2024.PubMed/NCBI View Article : Google Scholar

36 

Sęczyk Ł, Sugier D, Świeca M and Gawlik-Dziki U: The effect of in vitro digestion, food matrix, and hydrothermal treatment on the potential bioaccessibility of selected phenolic compounds. Food Chem. 344(128581)2021.PubMed/NCBI View Article : Google Scholar

37 

Song P, Huang Y, Li J, Shan S, Zhou Z, Cao H and Zhao C: The influence of processing technologies on the biological activity of carbohydrates in food. Food Chem X. 23(101590)2024.PubMed/NCBI View Article : Google Scholar

38 

Chen X, Zhang W, Quek SY and Zhao L: Flavor-food ingredient interactions in fortified or reformulated novel food: Binding behaviors, manipulation strategies, sensory impacts, and future trends in delicious and healthy food design. Compr Rev Food Sci Food Saf. 22:4004–4029. 2023.PubMed/NCBI View Article : Google Scholar

39 

Urminská D, Haring N, Fábry V and Urminská J: Fermentable oligosaccharides, disaccharides, monosaccharides and polyols and their role in food digestion. J Microbiol Biotech Food Sci. 11(e5521)2022.

40 

Borer KT: Relevance of milk composition to human longitudinal growth from infancy through puberty: Facts and controversies. Nutrients. 17(827)2025.PubMed/NCBI View Article : Google Scholar

41 

Romero-Velarde E, Delgado-Franco D, García-Gutiérrez M, Gurrola-Díaz C, Larrosa-Haro A, Montijo-Barrios E Muskiet FAJ, Vargas-Guerrero B and Geurts J: The importance of lactose in the human diet: Outcomes of a Mexican consensus meeting. Nutrients. 11(2737)2019.PubMed/NCBI View Article : Google Scholar

42 

Stanhope KL, Griffen SC, Bair BR, Swarbrick MM, Keim NL and Havel PJ: Twenty-four-hour endocrine and metabolic profiles following consumption of high-fructose corn syrup-, sucrose-, fructose-, and glucose-sweetened beverages with meals. Am J Clin Nutr. 87:1194–1203. 2008.PubMed/NCBI View Article : Google Scholar

43 

Khorshidian N, Shadnoush M, Zabihzadeh Khajavi M, Sohrabvandi S, Yousefi M and Mortazavian AM: Fructose and high fructose corn syrup: Are they a two-edged sword? Int J Food Sci Nutr. 72:592–614. 2021.PubMed/NCBI View Article : Google Scholar

44 

Aghaei B, Moradi F, Soleimani D, Moradinazar M, Khosravy T and Samadi M: Glycemic index, glycemic load, dietary inflammatory index, and risk of infertility in women. Food Sci Nutr. 11:6413–6424. 2023.PubMed/NCBI View Article : Google Scholar

45 

Grembecka M: Natural sweeteners in a human diet. Rocz Panstw Zakl Hig. 66:195–202. 2015.PubMed/NCBI

46 

den Berghe GV: How does blood glucose control with insulin save lives in intensive care? J Clin Invest. 114:1187–1195. 2004.PubMed/NCBI View Article : Google Scholar

47 

Wirfält E, McTaggart A, Pala V, Gullberg B, Frasca G, Panico S, Bueno-de-Mesquita H, Peeters PHM, Engeset D, Skeie G, et al: Food sources of carbohydrates in a European cohort of adults. Public Health Nutr. 5:1197–1215. 2002.PubMed/NCBI View Article : Google Scholar

48 

Sünram-Lea SI, Foster JK, Durlach P and Perez C: Glucose facilitation of cognitive performance in healthy young adults: Examination of the influence of fast-duration, time of day and pre-consumption plasma glucose levels. Psychopharmacology (Berl). 157:46–54. 2001.PubMed/NCBI View Article : Google Scholar

49 

Alwahsh SM and Gebhardt R: Dietary fructose as a risk factor for non-alcoholic fatty liver disease (NAFLD). Arch Toxicol. 91:1545–1563. 2017.PubMed/NCBI View Article : Google Scholar

50 

Yu S, Li C, Ji G and Zhang L: The contribution of dietary fructose to non-alcoholic fatty liver disease. Front Pharmacol. 12(783393)2021.PubMed/NCBI View Article : Google Scholar

51 

Rizkalla SW: Health implications of fructose consumption: A review of recent data. Nutr Metab (Lond). 7(82)2010.PubMed/NCBI View Article : Google Scholar

52 

Liu G, Hale GE and Hughes CL: Galactose metabolism and ovarian toxicity. Reprod Toxicol. 14:377–384. 2000.PubMed/NCBI View Article : Google Scholar

53 

Jiang Y, Pan Y, Rhea PR, Tan L, Gagea M, Cohen L and Yang P: A sucrose-enriched diet promotes tumorigenesis in mammary gland in part through the 12-lipoxygenase pathway. Cancer Res. 76:24–29. 2016.PubMed/NCBI View Article : Google Scholar

54 

Qi X and Tester RF: Lactose, maltose, and sucrose in health and disease. Mol Nutr Food Res. 64(1901082)2020.PubMed/NCBI View Article : Google Scholar

55 

Misra V, Shrivastava AK, Shukla SP and Ansari MI: Effect of sugar intake towards human health. Saudi J Med. 1:29–36. 2016.

56 

Misselwitz B, Butter M, Verbeke K and Fox MR: Update on lactose malabsorption and intolerance: Pathogenesis, diagnosis and clinical management. Gut. 68:2080–2091. 2019.PubMed/NCBI View Article : Google Scholar

57 

Poothullil JM: Maltose: The primary signal of hunger and satiation in human beings. Physiol Behav. 52:27–31. 1992.PubMed/NCBI View Article : Google Scholar

58 

Costa GT, Guimarães SB and de Carvalho Sampaio HA: Fructo-oligosaccharide effects on blood glucose: An overview. Acta Cir Bras. 27:279–282. 2012.PubMed/NCBI View Article : Google Scholar

59 

Niittynen L, Kajander K and Korpela R: Galacto-oligosaccharides and bowel function. Scand J Food Nutr. 51:62–66. 2007.

60 

Otles S and Ozgoz S: Health effects of dietary fiber. Acta Sci Pol Technol Aliment. 13:191–202. 2014.PubMed/NCBI

61 

Anderson JW, Baird P, Davis RH JR, Ferreri S, Knudtson M, Koraym A, Waters V and Williams CL: Health benefits of dietary fiber. Nutr Rev. 67:188–205. 2009.PubMed/NCBI View Article : Google Scholar

62 

Delzenne NM, Bindels LB, Neyrinck AM and Walter J: The gut microbiome and dietary fibers: implications in obesity, cardiometabolic diseases and cancer. Nat Rev Microbiol. 23:225–238. 2024.PubMed/NCBI View Article : Google Scholar

63 

Tan Z, Yang C, Zhao Y, Yang X and Li T: Interactional effects of food macronutrients with gut microbiome: Implications for host health and risk. J Agric Food Chem. 73:19109–19132. 2025.PubMed/NCBI View Article : Google Scholar

64 

Mora-Flores LP, Moreno-Terrazas Casildo R, Fuentes-Cabrera J, Pérez-Vicente HA, de Anda-Jáuregui G and Neri-Torres EE: The role of carbohydrate intake on the gut microbiome: A weight of evidence systematic review. Microorganisms. 11(1728)2023.PubMed/NCBI View Article : Google Scholar

65 

Frayn KN: Understanding human metabolism. Cambridge University Press, Cambridge, 2022.

66 

Wilkinson JG and Liebman M: Carbohydrate metabolism in sport and exercise. In: Nutrition in Exercise and Sport, third edition. CRC Press, Boca Raton, FL, pp63-99, 2022.

67 

Garrido G, Guzmán M and Odriozola JM: Effect of different types of high carbohydrate diets on glycogen metabolism in liver and skeletal muscle of endurance-trained rats. Eur J Appl Physiol Occup Physiol. 74:91–99. 1996.PubMed/NCBI View Article : Google Scholar

68 

Paoli A, Bosco G, Camporesi EM and Mangar D: Ketosis, ketogenic diet and food intake control: A complex relationship. Front Psychol. 6(27)2015.PubMed/NCBI View Article : Google Scholar

69 

Dreher ML: Whole fruits and fruit fiber emerging health effects. Nutrients. 10(1833)2018.PubMed/NCBI View Article : Google Scholar

70 

Yu W: Metabolic effects in C57B/6J mice fed a high-fat diet supplemented with chromium picolinate and chromium yeast. Honors College Thesis, 2019. https://ir.library.oregonstate.edu/concern/honors_college_theses/s1784s179.

71 

Baky MH, Salah M, Ezzelarab N, Shao P, Elshahed MS and Farag MA: Insoluble dietary fibers: structure, metabolism, interactions with human microbiome, and role in gut homeostasis. Crit Rev Food Sci Nutr. 64:1954–1968. 2024.PubMed/NCBI View Article : Google Scholar

72 

Yao Y, Cai X, Fei W, Ye Y, Zhao M and Zheng C: The role of short-chain fatty acids in immunity, inflammation and metabolism. Crit Rev Food Sci Nutr. 62:1–12. 2022.PubMed/NCBI View Article : Google Scholar

73 

Song M, Wu K, Meyerhardt JA, Ogino S, Wang M, Fuchs CS and Chan AT: Fiber intake and survival after colorectal cancer diagnosis. JAMA Oncol. 4:71–79. 2018.PubMed/NCBI View Article : Google Scholar

74 

Tily H, Patridge E, Cai Y, Gopu V, Gline S, Genkin M, Lindau H, Sjue A, Slavov I and Perlina A: Gut microbiome activity contributes to prediction of individual variation in glycemic response in adults. Diabetes Ther. 13:89–111. 2022.PubMed/NCBI View Article : Google Scholar

75 

Carmody RN, Varady K and Turnbaugh PJ: Digesting the complex metabolic effects of diet on the host and microbiome. Cell. 187:3857–3876. 2024.PubMed/NCBI View Article : Google Scholar

76 

Ludwig DS, Apovian CM, Aronne LJ, Astrup A, Cantley LC, Ebbeling CB, Heymsfield SB, Johnson JD, King JC, Krauss RM, et al: Competing paradigms of obesity pathogenesis: Energy balance versus carbohydrate-insulin models. Eur J Clin Nutr. 76:1209–1221. 2022.PubMed/NCBI View Article : Google Scholar

77 

Ludwig DS: Carbohydrate-insulin model: Does the conventional view of obesity reverse cause and effect? Philos Trans R Soc Lond B Biol Sci. 378(20220212)2023.PubMed/NCBI View Article : Google Scholar

78 

World Health Organization: Sugars intake for adults and children. Geneva, 2015. https://www.who.int/publications/i/item/9789241549028.

79 

Ludwig DS, Hu FB, Tappy L and Brand-Miller J: Dietary carbohydrates: Role of quality and quantity in chronic disease. BMJ. 361(k2340)2018.PubMed/NCBI View Article : Google Scholar

80 

Williams KA, Fughhi I, Fugar S, Mazur M, Gates S, Sawyer S, Patel H, Chambers D, McDaniel R, Reiser JR, et al: Nutrition intervention for reduction of cardiovascular risk in african americans using the 2019 American college of cardiology/american heart association primary prevention guidelines. Nutrients. 13(3422)2021.PubMed/NCBI View Article : Google Scholar

81 

Singh M, Hung ES, Cullum A, Allen RE, Aggett PJ, Dyson P, Forouhi NG, Greenwood DC, Pryke R, Taylor R, Twenefour D, et al: Lower carbohydrate diets for adults with type 2 diabetes. Br J Nutr. 127:1352–1357. 2021.PubMed/NCBI View Article : Google Scholar

82 

Dehghan M, Mente A, Zhang X, Swaminathan S, Li W, Mohan V, Iqbal R, Kumar R, Wentzel-Viljoen E, Rosengren A, et al: Associations of fats and carbohydrate intake with cardiovascular disease and mortality in 18 countries from five continents (PURE): A prospective cohort study. Lancet. 390:2050–2062. 2017.PubMed/NCBI View Article : Google Scholar

83 

Swaminathan S, Dehghan M, Raj JM, Thomas T, Rangarajan S, Jenkins D, Mony P, Mohan V, Lear SA, Avezum A, et al: Associations of cereal grains intake with cardiovascular disease and mortality across 21 countries in prospective urban and rural epidemiology study: Prospective cohort study. BMJ. 372(m4948)2021.PubMed/NCBI View Article : Google Scholar

84 

Malik VS, Li Y, Pan A, De Koning L, Schernhammer E, Willett WC and Hu FB: Long-term consumption of sugar-sweetened and artificially sweetened beverages and risk of mortality in US adults. Circulation. 139:2113–2125. 2019.PubMed/NCBI View Article : Google Scholar

85 

Yin J, Zhu Y, Malik V, Li X, Peng X, Zhang FF, Shan Z and Liu L: Intake of sugar-sweetened and low-calorie sweetened beverages and risk of cardiovascular disease: A meta-analysis and systematic review. Adv Nutr. 12:89–101. 2021.PubMed/NCBI View Article : Google Scholar

86 

Mahzari M and Mamun A: Does consumption of refined carbohydrates predict the incidence of type 2 diabetes mellitus? A systematic review and meta-analysis. Rom J Diabetes Nutr Metab Dis. 27:168–179. 2020.

87 

Maffetone P and Laursen PB: Refined carbohydrates and the overfat pandemic: Implications for brain health and public health policy. Front Public Health. 13(1585680)2025.PubMed/NCBI View Article : Google Scholar

88 

Lane MM, Gamage E, Du S, Ashtree DN, McGuinness AJ, Gauci S, Baker P, Lawrence M, Rebholz CM, Srour B, et al: Ultra-processed food exposure and adverse health outcomes: Umbrella review of epidemiological meta-analyses. BMJ. 384(e077310)2024.PubMed/NCBI View Article : Google Scholar

89 

Juul F, Vaidean G, Lin Y, Deierlein AL and Parekh N: Ultra-processed foods and incident cardiovascular disease in the framingham offspring study. J Am Coll Cardiol. 77:1520–1531. 2021.PubMed/NCBI View Article : Google Scholar

90 

Lacroix S, Cantin J and Nigam A: Contemporary issues regarding nutrition in cardiovascular rehabilitation. Ann Phys Rehabil Med. 60:36–42. 2017.PubMed/NCBI View Article : Google Scholar

91 

Maughan R: Carbohydrate metabolism. Surgery (Oxf). 27:6–10. 2009.

92 

Bolaños JP, Almeida A and Moncada S: Glycolysis: A bioenergetic or a survival pathway? Trends Biochem Sci. 35:145–149. 2010.PubMed/NCBI View Article : Google Scholar

93 

Chandel NS: Glycolysis. Cold Spring Harb Perspect Biol. 13(a040535)2021.PubMed/NCBI View Article : Google Scholar

94 

Akram M, Ali Shah SM, Munir N, Daniyal M, Tahir IM, Mahmood Z, Irshad M, Akhlaq M, Sultana S and Zainab R: Hexose monophosphate shunt, the role of its metabolites and associated disorders: A review. J Cell Physiol. 234:14473–14482. 2019.PubMed/NCBI View Article : Google Scholar

95 

Machado MG: The role of acetate in macrophages response against Streptococcus pneumoniae. Human health and pathology (unpublished thesis). Université de Lille, 2022.

96 

Dashty M: A quick look at biochemistry: Carbohydrate metabolism. Clin Biochem. 46:1339–1352. 2013.PubMed/NCBI View Article : Google Scholar

97 

Stephen AM, Champ MMJ, Cloran SJ, Fleith M, van Lieshout L, Mejborn H and Burley VJ: Dietary fibre in Europe: Current state of knowledge on definitions, sources, recommendations, intakes and relationships to health. Nutr Res Rev. 30:149–190. 2017.PubMed/NCBI View Article : Google Scholar

98 

Theodorakis N, Kreouzi M, Pappas A and Nikolaou M: Beyond calories: Individual metabolic and hormonal adaptations driving variability in weight management-a state-of-the-art narrative review. Int J Mol Sci. 25(13438)2024.PubMed/NCBI View Article : Google Scholar

99 

Vergari E, Knudsen JG, Ramracheya R, Salehi A, Zhang Q, Adam J, Asterholm IW, Benrick A, Briant LJ, Chibalina MV, et al: Insulin inhibits glucagon release by SGLT2-induced stimulation of somatostatin secretion. Nat Commun. 10(139)2019.PubMed/NCBI View Article : Google Scholar

100 

Tiller NB, Roberts JD, Beasley L, Chapman S, Pinto JM, Smith L, Wiffin M, Russell M, Sparks SA, Duckworth L, et al: International society of sports nutrition position stand: Nutritional considerations for single-stage ultra-marathon training and racing. J Int Soc Sports Nutr. 16(50)2019.PubMed/NCBI View Article : Google Scholar

101 

Tappy L: Metabolism of sugars: A window to the regulation of glucose and lipid homeostasis by splanchnic organs. Clin Nutr. 40:1691–1698. 2021.PubMed/NCBI View Article : Google Scholar

102 

Li Z, Fan X, Gao F, Pan S, Ma X, Cheng H, Nakatsukasa H, Zhang W and Zhang D: Fructose metabolism and its roles in metabolic diseases, inflammatory diseases, and cancer. Mol Biomed. 6(43)2025.PubMed/NCBI View Article : Google Scholar

103 

Cirillo P, Gersch MS, Mu W, Scherer PM, Kim KM, Gesualdo L, Henderson GN, Johnson RJ and Sautin YY: Ketohexokinase-dependent metabolism of fructose induces proinflammatory mediators in proximal tubular cells. J Am Soc Nephrol. 20:545–553. 2009.PubMed/NCBI View Article : Google Scholar

104 

Federico A, Rosato V, Masarone M, Torre P, Dallio M, Romeo M and Persico M: The role of fructose in non-alcoholic steatohepatitis: Old relationship and new insights. Nutrients. 13(1314)2021.PubMed/NCBI View Article : Google Scholar

105 

Tappy L and Lê KA: Metabolic effects of fructose and the worldwide increase in obesity. Physiol Rev. 90:23–46. 2010.PubMed/NCBI View Article : Google Scholar

106 

Zhu Z, Zhang X, Pan Q, Zhang L and Chai J: In-depth analysis of de novo lipogenesis in non-alcoholic fatty liver disease: Mechanism and pharmacological interventions. Liver Res. 7:285–295. 2023.PubMed/NCBI View Article : Google Scholar

107 

Khitan Z and Kim DH: Fructose: A key factor in the development of metabolic syndrome and hypertension. J Nutr Metab. 2013(682673)2013.PubMed/NCBI View Article : Google Scholar

108 

Takir M, Kostek O, Ozkok A, Elcioglu OC, Bakan A, Erek A, Mutlu HH, Telci O, Semerci A, Odabas AR, et al: Lowering uric acid with allopurinol improves insulin resistance and systemic inflammation in asymptomatic hyperuricemia. J Investig Med. 63:924–929. 2015.PubMed/NCBI View Article : Google Scholar

109 

Kim YJ, Jung DH and Park CS: Important roles of Ruminococcaceae in the human intestine for resistant starch utilization. Food Sci Biotechnol. 33:2009–2019. 2024.PubMed/NCBI View Article : Google Scholar

110 

Bedu-Ferrari C, Biscarrat P, Pepke F, Vati S, Chaudemanche C, Castelli F, Chollet C, Rué O, Hennequet-Antier C, Langella P and Cherbuy C: In-depth characterization of a selection of gut commensal bacteria reveals their functional capacities to metabolize dietary carbohydrates with prebiotic potential. mSystems. 9(e0140123)2024.PubMed/NCBI View Article : Google Scholar

111 

Liu L, Sun T, Liu H, Li J and Tian L: Carbohydrate quality vs quantity on cancer risk: Perspective of microbiome mechanisms. J Funct Foods. 118(106246)2024.

112 

Pavani M, Geethika KV, Ramya D, Patibandla J and Sunitha A: The role of carbohydrate intake in obesity: Implications for diet and weight management. J Integral Sci. 8:16–21. 2025.

113 

Burkitt DP and Trowell HC: Dietary fibre and western diseases. Ir Med J. 70:272–277. 1977.PubMed/NCBI

114 

Painter NS and Burkitt DP: Diverticular disease of the colon: A deficiency disease of western civilization. Br Med J. 2:450–454. 1971.PubMed/NCBI View Article : Google Scholar

115 

Veronese N, Gianfredi V, Solmi M, Barbagallo M, Dominguez LJ, Mandalà C, Di Palermo C, Carruba L, Solimando L, Stubbs B, et al: The impact of dietary fiber consumption on human health: An umbrella review of evidence from 17,155,277 individuals. Clin Nutr. 51:325–333. 2025.PubMed/NCBI View Article : Google Scholar

116 

Tao J, Quan J, El Helali A, Lam WWT and Pang H: Global trends indicate increasing consumption of dietary sodium and fiber in middle-income countries: A study of 30-year global macrotrends. Nutr Res. 118:63–69. 2023.PubMed/NCBI View Article : Google Scholar

117 

Schönenberger KA, Huwiler VV, Reber E, Mühlebach S, Stanga Z, Pestoni G and Faeh D: Dietary fibre intake and its association with ultraprocessed food consumption in the general population of Switzerland: Analysis of a population-based, cross-sectional national nutrition survey. BMJ Nutr Prev Health. 7:26–37. 2024.PubMed/NCBI View Article : Google Scholar

118 

Cifuentes L and O'Keefe S: Analysis of 1999-2017 NHANES data: Minimal increase and racial disparities in U.S. Fiber consumption over 18 years. Nutr Cancer. 76:345–351. 2024.PubMed/NCBI View Article : Google Scholar

119 

Guzmán C, Espinoza J and Fuentealba F: Pilot study to estimate dietary fiber intake in adults residing in chile. Nutrients. 15(900)2023.PubMed/NCBI View Article : Google Scholar

120 

Guzmán C, Espinoza J, Durán-Agüero S, Obregón AM and Fuentealba F: Dietary fiber intake in chile: 13 years after the last national report. Nutrients. 15(3671)2023.PubMed/NCBI View Article : Google Scholar

121 

Stribling P and Ibrahim F: Dietary fibre definition revisited-The case of low molecular weight carbohydrates. Clin Nutr ESPEN. 55:340–356. 2023.PubMed/NCBI View Article : Google Scholar

122 

Li L, Yan S, Liu S, Wang P, Li W, Yi Y and Qin S: In-depth insight into correlations between gut microbiota and dietary fiber elucidates a dietary causal relationship with host health. Food Res Int. 172(113133)2023.PubMed/NCBI View Article : Google Scholar

123 

Xie L, Alam MJ, Marques FZ and Mackay CR: A major mechanism for immunomodulation: Dietary fibres and acid metabolites. Semin Immunol. 66(101737)2023.PubMed/NCBI View Article : Google Scholar

124 

Gill SK, Rossi M, Bajka B and Whelan K: Dietary fiber in gastrointestinal health and disease. Nat Rev Gastroenterol Hepatol. 18:101–116. 2020.PubMed/NCBI View Article : Google Scholar

125 

Schneider E, Balasubramanian R, Ferri A, Cotter PD, Clarke G and Cryan JF: Fiber & fermented foods: Differential effects on the microbiota-gut-brain axis. Proc Nutr Soc. 84:365–380. 2025.PubMed/NCBI View Article : Google Scholar

126 

Deng M, Dan L, Ye S, Chen X, Wang X, Tian L and Chen J: Higher fiber intake is associated with reduced risk of related surgery among individuals with inflammatory bowel disease in a prospective cohort study. J Nutr. 153:2274–2282. 2023.PubMed/NCBI View Article : Google Scholar

127 

Deehan EC, Mocanu V and Madsen KL: Effects of dietary fiber on metabolic health and obesity. Nat Rev Gastroenterol Hepatol. 21:301–318. 2024.PubMed/NCBI View Article : Google Scholar

128 

Sharma D, Sharma L, Banerjee D and Dhama K: Effect of dietary fiber on obese/overweight persons and its mechanism of action: A systematic and meta-analysis on randomized controlled trials. Nutr Clin Métabol. 39:164–179. 2025.

129 

Liu M: A review of the effects of dietary fiber on type 2 diabetes. Theor Nat Sci. 124:114–119. 2025.

130 

Miketinas DC, Tucker WJ, Douglas CC and Patterson MA: Usual dietary fibre intake according to diabetes status in USA adults-NHANES 2013-2018. Br J Nutr. 130:1056–1064. 2023.PubMed/NCBI View Article : Google Scholar

131 

Biscarrat P, Bedu-Ferrari C, Langella P and Cherbuy C: Pulses: A way to encourage sustainable fiber consumption. Trends Food Sci Technol. 143(104281)2024.

132 

Sempio R, Segura Godoy C, Nyhan L, Sahin AW, Zannini E, Walter J and Arendt EK: Closing the fibre gap-the impact of combination of soluble and insoluble dietary fibre on bread quality and health benefits. Foods. 13(1980)2024.PubMed/NCBI View Article : Google Scholar

133 

Wang Y, Jian C, Salonen A, Dong M and Yang Z: Designing healthier bread through the lens of the gut microbiota. Trends Food Sci Technol. 134:13–28. 2023.

134 

Wang J, He S, Tao S, Ma S, Luo Y, Wu M and Zhou M: Structural, physicochemical, prebiotic properties of guava pulp insoluble dietary fiber and its quality enhancement ability on cow/goat yogurt: Impacts of ultrasound-assisted enzyme treatment. Food Biosci. 58(103797)2024.

135 

Aksornkitti V, Visuthranukul C, Leelahavanichkul A, Joyjinda Y and Sriswasdi S: Gut microbiome enterotypes and temporal variations during a six-month inulin-supplemented weight loss randomized controlled trial in Thai children with obesity. Comput Struct Biotechnol J. 27:5007–5019. 2025.PubMed/NCBI View Article : Google Scholar

136 

Wu X, Li S, Chen L, Ma S, Ma B, Song L and Qian D: Stereoselective construction of multifunctional C-glycosides enabled by nickel-catalyzed tandem borylation/glycosylation. J Am Chem Soc. 146:22413–22423. 2024.PubMed/NCBI View Article : Google Scholar

137 

van Kooyk Y and Rabinovich GA: Protein-glycan interactions in the control of innate and adaptive immune responses. Nat Immunol. 9:593–601. 2008.PubMed/NCBI View Article : Google Scholar

138 

Fernández-Tejada A, Cañada FJ and Jiménez Barbero J: Glycans in medicinal chemistry: An underexploited resource. ChemMedChem. 10:1291–1295. 2015.PubMed/NCBI View Article : Google Scholar

139 

Vasanthan RJ, Pradhan S and Thangamuthu MD: Emerging aspects of triazole in organic synthesis: Exploring its potential as a gelator. Curr Org Synth. 21:456–512. 2024.PubMed/NCBI View Article : Google Scholar

140 

LaMoia TE and Shulman GI: Cellular and molecular mechanisms of metformin action. Endocr Rev. 42:77–96. 2021.PubMed/NCBI View Article : Google Scholar

141 

Shurrab NT and Arafa ESA: Metformin: A review of its therapeutic efficacy and adverse effects. Obes Med. 17(100186)2020.

142 

Magliocca S, De Caro C, Lazzarato L, Russo R, Rolando B, Chegaev K, Marini E, Nieddu M, Burrai L, Boatto G, et al: Aceclofenac-galactose conjugate: design, synthesis, characterization, and pharmacological and toxicological evaluations. Mol Pharm. 15:3101–3110. 2018.PubMed/NCBI View Article : Google Scholar

143 

Klyosov AA: Carbohydrates and drug design. ACS Symp Ser. 1021:3–22. 2012.

144 

Ajaykumar C: Overview on the side effects of doxorubicin. IntechOpen, 2021.

145 

Putri SA, Purnomo RW and Savitri IJ: The potential of sucralfate as adjunctive therapy in the treatment of periodontal disease: A review. World J Adv Res Rev. 25:490–495. 2025.

146 

Cao X, Du X, Jiao H, An Q, Chen R, Fang P, Wang J and Yu B: Carbohydrate-based drugs launched during 2000-2021. Acta Pharm Sin B. 12:3783–3821. 2022.PubMed/NCBI View Article : Google Scholar

147 

Panesar PS and Kumari S: Lactulose: Production, purification and potential applications. Biotechnol Adv. 29:940–948. 2011.PubMed/NCBI View Article : Google Scholar

148 

Ruszkowski J and Witkowski JM: Lactulose: Patient- and dose-dependent prebiotic properties in humans. Anaerobe. 59:100–106. 2019.PubMed/NCBI View Article : Google Scholar

149 

Bregman DB and Goodnough LT: Experience with intravenous ferric carboxymaltose in patients with iron deficiency anemia. Ther Adv Hematol. 5:48–60. 2014.PubMed/NCBI View Article : Google Scholar

150 

Boots JMM and Quax RAM: High-dose intravenous iron with either ferric carboxymaltose or ferric derisomaltose: A benefit-risk assessment. Drug Saf. 45:1019–1036. 2022.PubMed/NCBI View Article : Google Scholar

151 

Patocka J, Nepovimova E, Wu W and Kuca K: Digoxin: Pharmacology and toxicology-a review. Environ Toxicol Pharmacol. 79(103400)2020.PubMed/NCBI View Article : Google Scholar

152 

Hricovíni M: Structural aspects of carbohydrates and the relation with their biological properties. Curr Med Chem. 11:2565–2583. 2004.PubMed/NCBI View Article : Google Scholar

153 

Donat F, Duret JP, Santoni A, Cariou R, Necciari J, Magnani H and de Greef R: The pharmacokinetics of fondaparinux sodium in healthy volunteers. Clin Pharmacokinet. 41 (Suppl 2):S1–S9. 2002.PubMed/NCBI View Article : Google Scholar

154 

Anderson VR and Perry CM: Pentosan polysulfate: A review of its use in the relief of bladder pain or discomfort in interstitial cystitis. Drugs. 66:821–835. 2006.PubMed/NCBI View Article : Google Scholar

155 

Putra ON, Musfiroh I, Elisa S, Musa M, Ikram EHK, Chaidir C and Muchtaridi M: Sodium starch glycolate (SSG) from sago starch (metroxylon sago) as a superdisintegrant: Synthesis and characterization. Molecules. 29(151)2023.PubMed/NCBI View Article : Google Scholar

156 

Stallforth P, Lepenies B, Adibekian A and Seeberger PH: 2009 Claude S. Hudson award in carbohydrate chemistry. Carbohydrates: A frontier in medicinal chemistry. J Med Chem. 52:5561–5577. 2009.PubMed/NCBI View Article : Google Scholar

157 

Campbell H and Carter H: Rational use of haemophilus influenzae type b vaccine. Drugs. 46:378–383. 1993.PubMed/NCBI View Article : Google Scholar

158 

Pifferi C, Fuentes R and Fernández-Tejada A: Natural and synthetic carbohydrate-based vaccine adjuvants and their mechanisms of action. Nat Rev Chem. 5:197–216. 2021.PubMed/NCBI View Article : Google Scholar

159 

Pan L, Cai C, Liu C, Liu D, Li G, Linhardt RJ and Yu G: Recent progress and advanced technology in carbohydrate-based drug development. Curr Opin Biotechnol. 69:191–198. 2021.PubMed/NCBI View Article : Google Scholar

160 

Maxwell EG, Colquhoun IJ, Chau HK, Hotchkiss AT, Waldron KW, Morris VJ and Belshaw NJ: Modified sugar beet pectin induces apoptosis of colon cancer cells via an interaction with the neutral sugar side-chains. Carbohydr Polym. 136:923–929. 2016.PubMed/NCBI View Article : Google Scholar

161 

Ji X, Peng Q, Yuan Y, Shen J, Xie X and Wang M: Isolation, structures and bioactivities of the polysaccharides from jujube fruit (Ziziphus jujuba Mill.): A review. Food Chem. 227:349–357. 2017.PubMed/NCBI View Article : Google Scholar

162 

Shao P, Chen X and Sun P: Chemical characterization, antioxidant and antitumor activity of sulfated polysaccharide from Sargassum horneri. Carbohydr Polym. 105:260–269. 2014.PubMed/NCBI View Article : Google Scholar

163 

Shao P, Pei Y, Fang Z and Sun P: Effects of partial desulfation on antioxidant and inhibition of DLD cancer cell of Ulva fasciata polysaccharide. Int J Biol Macromol. 65:307–313. 2014.PubMed/NCBI View Article : Google Scholar

164 

Yu Y, Shen M, Song Q and Xie J: Biological activities and pharmaceutical applications of polysaccharide from natural resources: A review. Carbohydr Polym. 183:91–101. 2018.PubMed/NCBI View Article : Google Scholar

165 

Bhavya PV, Rabecca Jenifer V, Ahmad Y and Mohan Das T: A simple perspective of glycosciences. J Indian Chem Soc. 97:157–176. 2020.

166 

Lalhmangaihzuala S, Vanlaldinpuia K, Khiangte V, Laldinpuii Z, Liana T, Lalhriatpuia C and Pachuau Z: Therapeutic applications of carbohydrate-based compounds: A sweet solution for medical advancement. Mol Divers. 28:4553–4579. 2024.PubMed/NCBI View Article : Google Scholar

167 

Chen Y, Song J, Chen X and Chen G: Synthetic glycopolymers in tumor immunotherapy. Macromol Rapid Commun. 46(e2401089)2025.PubMed/NCBI View Article : Google Scholar

168 

Hulugalla K, Abodunrin OD, Anderson J, Smith AE and Werfel T: A ‘sweeter’ approach to cancer immunotherapy: Glycopolymers as diverse tools for immune modulation. J Control Release. 388(114372)2025.PubMed/NCBI View Article : Google Scholar

169 

Bhirud D, Bhattacharya S and Prajapati BG: Bioengineered carbohydrate polymers for colon-specific drug release: Current trends and future prospects. J Biomed Mater Res A. 112:1860–1872. 2024.PubMed/NCBI View Article : Google Scholar

170 

Udaipuria N and Bhattacharya S: Novel carbohydrate polymer-based systems for precise drug delivery in colon cancer: Improving treatment effectiveness with intelligent biodegradable materials. Biopolymers. 116(e23632)2025.PubMed/NCBI View Article : Google Scholar

171 

Mishra VK, Khanna A, Tiwari G, Tyagi R and Sagar R: Recent developments on the synthesis of biologically active glycohybrids. Bioorg Chem. 145(107172)2024.PubMed/NCBI View Article : Google Scholar

172 

Plante OJ, Palmacci ER and Seeberger PH: Automated solid-phase synthesis of oligosaccharides. Science. 291:1523–1527. 2001.PubMed/NCBI View Article : Google Scholar

173 

Nokami T, Hayashi R, Saigusa Y, Shimizu A, Liu CY, Mong KKT and Yoshida JI: Automated solution-phase synthesis of oligosaccharides via iterative electrochemical assembly of thioglycosides. Org Lett. 15:4520–4523. 2013.PubMed/NCBI View Article : Google Scholar

174 

Tang SL, Linz LB, Bonning BC and Pohl NLB: Automated solution-phase synthesis of insect glycans to probe the binding affinity of pea enation mosaic virus. J Org Chem. 80:10482–10489. 2015.PubMed/NCBI View Article : Google Scholar

175 

Ganesh NV, Fujikawa K, Tan YH, Stine KJ and Demchenko AV: HPLC-assisted automated oligosaccharide synthesis. Org Lett. 14:3036–3039. 2012.PubMed/NCBI View Article : Google Scholar

176 

Panza M, Pistorio SG, Stine KJ and Demchenko AV: Automated chemical oligosaccharide synthesis: Novel approach to traditional challenges. Chem Rev. 118:8105–8150. 2018.PubMed/NCBI View Article : Google Scholar

177 

Hahm HS, Schlegel MK, Hurevich M, Eller S, Schuhmacher F, Hofmann J, Pagel K and Seeberger PH: Automated glycan assembly using the glyconeer 2.1 synthesizer. Proc Natl Acad Sci USA. 114:E3385–E3389. 2017.PubMed/NCBI View Article : Google Scholar

178 

Seeberger PH: The logic of automated glycan assembly. Acc Chem Res. 48:1450–1463. 2015.PubMed/NCBI View Article : Google Scholar

179 

Naresh K, Schumacher F, Hahm HS and Seeberger PH: Pushing the limits of automated glycan assembly: Synthesis of a 50mer polymannoside. Chem Commun (Camb). 53:9085–9088. 2017.PubMed/NCBI View Article : Google Scholar

180 

Guberman M and Seeberger PH: Automated glycan assembly: A perspective. J Am Chem Soc. 141:5581–5592. 2019.PubMed/NCBI View Article : Google Scholar

181 

Niggemeyer GB, Danglad-Flores JA and Seeberger PH: Automated synthesis of C1-functionalized oligosaccharides. J Am Chem Soc. 147:1649–1655. 2024.PubMed/NCBI View Article : Google Scholar

182 

Yuan L, Hua Y and Wang X: Recent progress of glycomimetics in drug development. Org Biomol Chem. 23:7671–7680. 2025.PubMed/NCBI View Article : Google Scholar

183 

Martínez-Pascual R, Valera-Zaragoza M, Fernández-Bolaños JG and López Ó: Exploring the chemistry and applications of Thio-, Seleno-, and tellurosugars. Molecules. 30(2053)2025.PubMed/NCBI View Article : Google Scholar

184 

Brandariz I and Iglesias E: Local anesthetics: Acid base behaviour and inclusion with cyclodextrin. Curr Org Chem. 17:3050–3063. 2013.

185 

Jacob S and Nair AB: Cyclodextrin complexes: Perspective from drug delivery and formulation. Drug Dev Res. 79:201–217. 2018.PubMed/NCBI View Article : Google Scholar

186 

Jansook P, Ogawa N and Loftsson T: Cyclodextrins: Structure, physicochemical properties and pharmaceutical applications. Int J Pharm. 535:272–284. 2018.PubMed/NCBI View Article : Google Scholar

187 

Gadade DD and Pekamwar SS: Cyclodextrin based nanoparticles for drug delivery and theranostics. Adv Pharm Bull. 10:166–183. 2020.PubMed/NCBI View Article : Google Scholar

188 

Mansourpour M, Mahjub R, Amini M, Ostad SN, Shamsa ES, Rafiee-Tehrani M and Dorkoosh FA: Development of acid-resistant alginate/trimethyl chitosan nanoparticles containing cationic β-cyclodextrin polymers for insulin oral delivery. AAPS PharmSciTech. 16:952–962. 2015.PubMed/NCBI View Article : Google Scholar

189 

Lahiri R, Ansari AA and Vankar YD: Recent developments in design and synthesis of bicyclic azasugars, carbasugars and related molecules as glycosidase inhibitors. Chem Soc Rev. 42:5102–5118. 2013.PubMed/NCBI View Article : Google Scholar

190 

Tamburrini A, Colombo C and Bernardi A: Design and synthesis of glycomimetics: Recent advances. Med Res Rev. 40:495–531. 2020.PubMed/NCBI View Article : Google Scholar

191 

Wali JA, Raubenheimer D, Senior AM, Le Couteur DG and Simpson SJ: Cardio-metabolic consequences of dietary carbohydrates: Reconciling contradictions using nutritional geometry. Cardiovasc Dis. 117:386–401. 2021.PubMed/NCBI View Article : Google Scholar

192 

Gao Y, Hua R, Hu K and Wang Z: Carbohydrates deteriorate fatty liver by activating the inflammatory response. Nutr Res Rev. 35:252–267. 2022.PubMed/NCBI View Article : Google Scholar

193 

Webster C: Preliminary investigations for studying the effects of low carbohydrate high fat diets on gluconeogenesis in type 2 diabetes patients (unpublished thesis). University of Cape Town, 2020.

194 

Bray GA, Fruhbeck G, Ryan DH and Wilding JPH: Management of obesity. Lancet. 387:1947–1956. 2016.

195 

Patnode CD, Evans CV, Senger CA, Redmond N and Lin JS: Behavioral counseling to promote a healthful diet and physical activity for cardiovascular disease prevention in adults without known cardiovascular disease risk factors: Updated evidence report and systematic review for the US preventive services task force. JAMA. 318:175–193. 2017.PubMed/NCBI View Article : Google Scholar

196 

Nakamura M and Sadoshima J: Cardiomyopathy in obesity, insulin resistance and diabetes. J Physiol. 598:2977–2993. 2020.PubMed/NCBI View Article : Google Scholar

197 

Liao Y: Computational modelling of fructose metabolism and lipid deposition in non-alcoholic fatty liver disease (unpublished thesis). University College London, 2021.

198 

Schwarz JM, Noworolski SM, Erkin-Cakmak A, Korn NJ, Wen MJ, Tai VW, Jones GM, Palii SP, Velasco-Alin M, Pan K, et al: Effects of dietary fructose restriction on liver fat, de novo lipogenesis, and insulin kinetics in children with obesity. Gastroenterology. 153:743–752. 2017.PubMed/NCBI View Article : Google Scholar

199 

Beysen C, Ruddy M, Stoch A, Mixson L, Rosko K, Riiff T, Turner SM, Hellerstein MK and Murphy EJ: Dose-dependent quantitative effects of acute fructose administration on hepatic de novo lipogenesis in healthy humans. Am J Physiol Endocrinol Metab. 315:E126–E132. 2018.PubMed/NCBI View Article : Google Scholar

200 

Geidl-Flueck B and Gerber PA: Fructose drives de novo lipogenesis affecting metabolic health. J Endocrinol. 257(e220270)2023.PubMed/NCBI View Article : Google Scholar

201 

Prinz P: Comments on ‘Fructose- and sucrose- but not glucose-sweetened beverages promote hepatic de novo lipogenesis-a randomized controlled trial’. J Hepatol. 75:753–754. 2021.PubMed/NCBI View Article : Google Scholar

202 

Brouwers MCGJ: Fructose 1-phosphate, an evolutionary signaling molecule of abundancy. Trends Endocrinol Metab. 33:680–689. 2022.PubMed/NCBI View Article : Google Scholar

203 

Iizuka K: The roles of carbohydrate response element binding protein in the relationship between carbohydrate intake and diseases. Int J Mol Sci. 22(12058)2021.PubMed/NCBI View Article : Google Scholar

204 

Coronati M, Baratta F, Pastori D, Ferro D, Angelico F and Del Ben M: Added fructose in non-alcoholic fatty liver disease and in metabolic syndrome: A narrative review. Nutrients. 14(1127)2022.PubMed/NCBI View Article : Google Scholar

205 

Zhao S, Jang C, Liu J, Uehara K, Gilbert M, Izzo L, Zeng X, Trefely S, Fernandez S, Carrer A, et al: Dietary fructose feeds hepatic lipogenesis via microbiota-derived acetate. Nature. 579:586–591. 2020.PubMed/NCBI View Article : Google Scholar

206 

Postic C: Conversion of a dietary fructose: New clues from the gut microbiome. Nat Metab. 2:217–218. 2020.PubMed/NCBI View Article : Google Scholar

207 

Pradhan S, Małecki JG and Mohan Das T: Highly selective iodide detection in solution and gel state using tuneable benzoate N-glucosides. Anal Sens. 6(e202500083)2026.

208 

V RJ, Malecki JG and Thangamuthu MD: Photo-responsive organogelator based on cholesterol incorporated sugar-azobenzene derivatives. Carbohydr Res. 549(109356)2025.PubMed/NCBI View Article : Google Scholar

209 

Bhavya PV, Malecki JG and Mohan Das T: Isoniazid-sugar-triazole-based fluorescent ‘turn-on’ chemosensor for Zn2+ and Mn2+ detection with potential biological applications. ChemistrySelect. 10(e202405443)2025.

210 

Pradhan S, Hussain F, Małecki JG and Mohan Das T: Pyridine hydrazide glycoconjugate-based gelators: Facile synthesis and exploring their application in iodide sensing. J Mol Liq. 416(126529)2024.

Related Articles

  • Abstract
  • View
  • Download
Copy and paste a formatted citation
Spandidos Publications style
Pradhan S, Anbalagan V, Venkatesh J and Mohan Das T: A simple perspective of carbohydrates in food and nutrition (Review). Int J Funct Nutr 7: 4, 2026.
APA
Pradhan, S., Anbalagan, V., Venkatesh, J., & Mohan Das, T. (2026). A simple perspective of carbohydrates in food and nutrition (Review). International Journal of Functional Nutrition, 7, 4. https://doi.org/10.3892/ijfn.2026.56
MLA
Pradhan, S., Anbalagan, V., Venkatesh, J., Mohan Das, T."A simple perspective of carbohydrates in food and nutrition (Review)". International Journal of Functional Nutrition 7.1 (2026): 4.
Chicago
Pradhan, S., Anbalagan, V., Venkatesh, J., Mohan Das, T."A simple perspective of carbohydrates in food and nutrition (Review)". International Journal of Functional Nutrition 7, no. 1 (2026): 4. https://doi.org/10.3892/ijfn.2026.56
Copy and paste a formatted citation
x
Spandidos Publications style
Pradhan S, Anbalagan V, Venkatesh J and Mohan Das T: A simple perspective of carbohydrates in food and nutrition (Review). Int J Funct Nutr 7: 4, 2026.
APA
Pradhan, S., Anbalagan, V., Venkatesh, J., & Mohan Das, T. (2026). A simple perspective of carbohydrates in food and nutrition (Review). International Journal of Functional Nutrition, 7, 4. https://doi.org/10.3892/ijfn.2026.56
MLA
Pradhan, S., Anbalagan, V., Venkatesh, J., Mohan Das, T."A simple perspective of carbohydrates in food and nutrition (Review)". International Journal of Functional Nutrition 7.1 (2026): 4.
Chicago
Pradhan, S., Anbalagan, V., Venkatesh, J., Mohan Das, T."A simple perspective of carbohydrates in food and nutrition (Review)". International Journal of Functional Nutrition 7, no. 1 (2026): 4. https://doi.org/10.3892/ijfn.2026.56
Follow us
  • Twitter
  • LinkedIn
  • Facebook
About
  • Spandidos Publications
  • Careers
  • Cookie Policy
  • Privacy Policy
How can we help?
  • Help
  • Live Chat
  • Contact
  • Email to our Support Team